Argos Therapeutics (ARGS) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 23, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	ARGOS THERAPEUTICS INC
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		19,688,802
Entity Public Float			$59,600,000
Amendment Flag	FALSE
Entity Central Index Key	1105533
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$37,223,590	$33,297,970
Short-term investments	19,016,347	13,659,812
Prepaid expenses	838,420	629,935
Deferred financing costs	309,927	1,516,424
Other receivables	129,019	424,501
Total current assets	57,517,303	49,528,642
Property and equipment, net	5,513,555	1,602,103
Restricted cash	1,325,000
Other assets	11,020	550
Total assets	64,366,878	51,131,295
Current liabilities
Accounts payable	1,860,491	1,317,072
Other accrued expenses	1,405,378	1,800,794
Current portion of notes payable	30,885	45,447
Total current liabilities	3,296,754	3,163,313
Long-term portion of notes payable	19,796,545	7,014,106
Long-term portion of manufacturing research and development obligation	3,475,552
Long-term portion of facility lease obligation	3,380,223
Deferred liability	3,066,000	3,066,000
Commitments
Stockholders’ (deficit) equity
Preferred stock $0.001 par value; 0 and 5,000,000 shares authorized as of December 31, 2013 and 2014; 0 shares issued and outstanding as of December 31, 2013 and 2014
Common stock $0.001 par value; 120,000,000 and 200,000,000 shares authorized as of December 31, 2013 and 2014; 235,707 and 19,657,412 shares issued and outstanding as of December 31, 2013 and 2014	19,657	236
Accumulated other comprehensive loss	-124,841	-102,531
Additional paid-in capital	235,627,174	75,189,950
Accumulated deficit	-204,170,186	-150,864,248
Total stockholders’ (deficit) equity	31,351,804	-75,776,593
Total liabilities, redeemable convertible preferred stock and stockholders’ (deficit) equity	64,366,878	51,131,295
Series A Preferred Stock [Member]
Current liabilities
Temporary stock		332,869
Series B Preferred Stock [Member]
Current liabilities
Temporary stock		5,521,437
Series C Preferred Stock [Member]
Current liabilities
Temporary stock		2,655,884
Series D Preferred Stock [Member]
Current liabilities
Temporary stock		33,262,492
Series E Preferred Stock [Member]
Current liabilities
Temporary stock		$71,891,787

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Temporary stock, authorized	0	160,700,000
Temporary stock, outstanding	0
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	120,000,000
Common stock, shares issued	19,657,412	235,707
Common stock, shares outstanding	19,657,412	235,707
Series A Preferred Stock [Member]
Temporary stock, par value (in Dollars per share)	$0.00	$0.00
Temporary stock, authorized	0	1,200,000
Temporary stock, issued	0	1,040,216
Temporary stock, outstanding	0	1,040,216
Temporary stock, liquidation preference (in Dollars)		$332,869
Series B Preferred Stock [Member]
Temporary stock, par value (in Dollars per share)	$0.00	$0.00
Temporary stock, authorized	0	18,500,000
Temporary stock, issued	0	9,803,688
Temporary stock, outstanding	0	9,803,688
Temporary stock, liquidation preference (in Dollars)		5,521,437
Series C Preferred Stock [Member]
Temporary stock, par value (in Dollars per share)	$0.00	$0.00
Temporary stock, authorized	0	40,000,000
Temporary stock, issued	0	28,716,679
Temporary stock, outstanding	0	28,716,679
Temporary stock, liquidation preference (in Dollars)		2,655,884
Series D Preferred Stock [Member]
Temporary stock, par value (in Dollars per share)	$0.00	$0.00
Temporary stock, authorized	0	31,000,000
Temporary stock, issued	0	21,040,817
Temporary stock, outstanding	0	21,040,817
Temporary stock, liquidation preference (in Dollars)		41,630,624
Series E Preferred Stock [Member]
Temporary stock, par value (in Dollars per share)	$0.00	$0.00
Temporary stock, authorized	0	70,000,000
Temporary stock, issued	0	56,011,258
Temporary stock, outstanding	0	56,011,258
Temporary stock, liquidation preference (in Dollars)		$72,945,310

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue	$1,974,019	$4,421,689	$7,039,010
Operating expenses
Research and development	45,498,916	23,991,151	17,616,892
General and administrative	8,599,359	4,662,317	6,135,581
Total operating expenses	54,098,275	28,653,468	23,752,473
Operating loss	-52,124,256	-24,231,779	-16,713,463
Other income (expense)
Interest income	66,580	7,184	4,604
Interest expense	-1,123,579	-4,705	-292,496
Change in fair value of warrant liability		355,352	4,916,785
Derivative (expense) income			1,036,403
Investment tax credits	140,556		694,331
Other expense	-265,239	-47,615	-117,494
Other income (expense), net	-1,181,682	310,216	6,242,133
Net loss	-53,305,938	-23,921,563	-10,471,330
Accretion of redeemable convertible preferred stock (See Note 19)	-863,226	4,772,991	-351,371
Less: Preferred stock dividend due to exchanges of preferred shares (See Note 19)		-14,726,088
Net loss attributable to common stockholders	($54,169,164)	($33,874,660)	($10,822,701)
Net loss attributable to common stockholders per share, basic and diluted (in Dollars per share)	($3.12)	($147.37)	($54.58)
Weighted average shares outstanding, basic and diluted (in Shares)	17,367,665	229,865	198,306

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net loss	($53,305,938)	($23,921,563)	($10,471,330)
Other comprehensive loss:
Foreign currency translation (loss) gain	-10,382	-8,264	-180,049
Unrealized (loss) on short-term investments	-11,928
Total comprehensive loss	($53,328,248)	($23,929,827)	($10,651,379)

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' (Deficit) Equity (USD $)	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Conversion of Preferred Stock Into Common Stock [Member]	Total
	Conversion of Preferred Stock Into Common Stock [Member]	Conversion of Warrants Into Common Stock [Member]		Conversion of Preferred Stock Into Common Stock [Member]	Conversion of Warrants Into Common Stock [Member]
Balance at Dec. 31, 2011			$122			$29,413,821	$85,782	($128,828,989)	$2,974,158		($96,355,106)
Balance (in Shares) at Dec. 31, 2011			122,345
Issuance of restricted stock						14,550					14,550
Issuance of options to nonemployees						561					561
Stock-based compensation						1,042,989					1,042,989
Conversion of preferred stock into common stock	105			8,067,829						8,067,934
Conversion of preferred stock into common stock (in Shares)	104,494
Accretion of preferred stock						-351,371					-351,371
Adjustment to additional paid in capital						17,306,478					17,306,478
Extinguishment of preferred shares								12,357,634			12,357,634
Purchase of noncontrolling interest’s shares						2,974,158			-2,974,158
Cumulative translation adjustment							-180,049				-180,049
Net loss								-10,471,330			-10,471,330
Balance at Dec. 31, 2012			227			58,469,015	-94,267	-126,942,685			-68,567,710
Balance (in Shares) at Dec. 31, 2012			226,839
Exercise of common stock options			2			5,791					5,793
Exercise of common stock options (in Shares)			1,379
Issuance of restricted stock			7			16,493					16,500
Issuance of restricted stock (in Shares)			7,571
Issuance of common warrants						618,155					618,155
Shares issued (in Shares)			-7
Surrender of shares (in Shares)			-75
Stock-based compensation						1,053,163					1,053,163
Reversal of prior accretion						5,657,638					5,657,638
Accretion of preferred stock						-884,647					4,772,991
Exchange of preferred shares						-14,726,088					-14,726,088
Reduction of liquidation value						24,980,430					24,980,430
Cumulative translation adjustment							-8,264				-8,264
Net loss								-23,921,563			-23,921,563
Balance at Dec. 31, 2013			236			75,189,950	-102,531	-150,864,248			-75,776,593
Balance (in Shares) at Dec. 31, 2013			235,707								235,707
Exercise of common stock options			3			12,807					12,810
Exercise of common stock options (in Shares)			3,050								3,050
Shares issued			6,229			49,823,571					49,829,800
Shares issued (in Shares)			6,228,725
Common stock issuance costs						-6,391,588					-6,391,588
Stock-based compensation						3,013,284					3,013,284
Conversion of preferred stock into common stock	13,188	1		114,514,267	-1					114,527,455
Conversion of preferred stock into common stock (in Shares)	13,188,251	1,679
Accretion of preferred stock						-863,226					-863,226
Adjustment to additional paid in capital						328,110					328,110
Cumulative translation adjustment							-10,382				-10,382
Unrealized loss on short-term investments							-11,928				-11,928
Net loss								-53,305,938			-53,305,938
Balance at Dec. 31, 2014			$19,657			$235,627,174	($124,841)	($204,170,186)			$31,351,804
Balance (in Shares) at Dec. 31, 2014			19,657,412								19,657,412

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net loss	($53,305,938)	($23,921,563)	($10,471,330)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	566,117	611,421	505,261
Compensation expense related to stock options and warrants	3,013,283	1,081,186	1,043,550
Amortization of debt issuance costs	69,308
Amortization of debt discount	24,917
Interest accrued on long-term debt	693,114
Write-off of deferred financing costs			1,785,779
Derivative expense (income)			-1,036,403
Noncash interest expense		2,465	292,064
Increase (decrease) in fair value of warrant liability		-355,352	-4,916,785
Issuance of restricted stock recorded as consulting expense		16,500	14,550
Loss (gain) on disposal of equipment	-1,710	-50,835	-4,774
Changes in operating assets and liabilities:
Prepaid expenses and other receivables	86,997	438,867	-216,332
Deferred financing costs		-571,327
Other assets	-10,471
Accounts payable	543,419	181,965	60,977
Accrued expenses	-395,416	1,244,940	-254,813
Long-term portion of manufacturing research and development obligation	3,475,552
Deferred liability		3,066,000
Net cash used in operating activities	-45,240,828	-18,255,733	-13,198,256
Cash flows from investing activities
Purchases of property and equipment	-1,097,798	-596,455	-1,137,533
Proceeds from sales of fixed assets	2,000	50,835	5,555
Purchases of short-term investments	-25,593,464	-13,600,941	-4,591,437
Payment to restricted cash account securing letter of credit	-1,325,000
Proceeds from sales and maturities of short-term investments	20,225,000	4,090,000	442,566
Net cash (used in) provided by investing activities	-7,789,262	-10,056,561	-5,280,849
Cash flows from financing activities
Proceeds from sale of common stock	49,829,800
Proceeds from sale of redeemable convertible preferred stock		47,409,867	25,000,000
Proceeds from issuance of common stock warrants		590,132
Stock issuance costs	-4,875,404	-1,501,344	-208,934
Proceeds from notes payable with detachable common stock warrants	12,500,000	6,934,000	95,756
Debt issuance costs	-449,796
Payments on notes payable	-51,481	-34,934	-15,568
Proceeds from exercise of common stock options	12,810	5,793
Net cash provided by financing activities	56,965,929	53,403,514	24,871,254
Effect of exchange rates changes on cash	-10,219	-8,115	-180,098
Net increase in cash and cash equivalents	3,925,620	25,083,105	6,212,051
Cash and cash equivalents
Beginning of period	33,297,970	8,214,865	2,002,814
End of period	37,223,590	33,297,970	8,214,865
Supplemental disclosure of cash flow information
Cash paid for interest	307,944	512	433
Supplemental disclosure of noncash investing and financing activities
Conversion of notes payable and accrued interest into preferred stock			10,668,185
Conversion of preferred stock into common stock	114,527,695		8,067,307
Preferred stock accretion	863,226	-4,772,991	351,371
Interest accrued on long-term debt	693,114
Recognition of asset and facility lease obligation related to construction of new property	$3,380,223

Note_1_Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Organization
	Argos Therapeutics, Inc. (the “Company”), was incorporated in the State of Delaware on May 8, 1997. The Company is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The Company’s most advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. The Company is developing a second Arcelis-based product candidate, AGS-004, for the treatment of HIV.
	Initial Public Offering
	In February 2014, the Company issued and sold 6,228,725 shares of its common stock, including 603,725 shares of common stock sold pursuant to the underwriters’ exercise of their option to purchase additional shares, in the Company’s initial public offering, at a public offering price of $8.00 per share, for aggregate gross proceeds of $49.8 million. The net offering proceeds to the Company, after deducting underwriting discounts and commissions of approximately $3.5 million and offering expenses of approximately $2.9 million, were approximately $43.4 million. Upon the closing of the initial public offering, all of the then-outstanding shares of the Company’s redeemable convertible preferred stock automatically converted into 13,188,251 shares of common stock.
	In connection with the initial public offering, the Company paid a former lender a $200,000 under a Loan and Security Agreement entered into with two lending institutions in April 2007. The Loan and Security Agreement terminated in April 2010, and the Company repaid all amounts owing under the Loan and Security Agreement. In connection with the Loan and Security Agreement, the Company was required to pay a success fee of $200,000 upon consummation of a liquidity event, including an initial public offering. Accordingly, the Company paid this fee in March 2014. The Company recorded this fee in Other expense on the Condensed Consolidated Statements of Operations during the year ended December 31, 2014.
	There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company expects to continue to incur losses and require additional financial resources to advance its products to either commercial stage or liquidity events.
	Capitalization
	In connection with the Company’s initial public offering in February 2014, the Company effected a one–for-six reverse split of its common stock. All references to shares of common stock outstanding, average number of shares outstanding and per share amounts in these consolidated financial statements and notes to consolidated financial statements have been restated to reflect the reverse split on a retroactive basis.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts and results of operations of the Company and DC Bio, formerly Merix Canada Corp., an unlimited liability corporation incorporated in the Province of Nova Scotia. Prior to October 26, 2012, the Company consolidated DC Bio under ASC 810-10-50, Consolidation of Variable Interest Entities (“VIE”), as DC Bio met the requirements of a VIE. As of December 31, 2012, the Company owned 100% of DC Bio through the repurchase of the noncontrolling interests of DC Bio. All intercompany balances and transactions have been eliminated in consolidation.
	Net Loss per Share
	Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less as of the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States of America or Canada. The Company maintains cash in accounts which are in excess of federally insured limits. As of December 31, 2013 and December 31, 2014, $33,047,970 and $36,973,590, respectively, in cash and cash equivalents was uninsured.
	Short-Term Investments
	All investments with original maturities less than one year from the balance sheet date are considered short-term investments. All short-term investments are classified as available-for-sale and therefore carried at fair value. Generally, the fair value of short-term investments approximates amortized cost. The Company primarily invests in high-quality marketable debt securities issued by high quality financial and industrial companies.
	Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments. Total cash and cash equivalent balances have exceeded insured balances by the Federal Depository Insurance Company (“FDIC”).
	Property and Equipment
	Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Property and equipment held under capital leases and leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. Repairs and maintenance costs are expensed as incurred.
	Impairment of Long-Lived Assets
	The Company periodically assesses the impairment of long lived assets in accordance with ASC Topic 360, Property Plant and Equipment. When indicators of impairment are present, the Company evaluates the carrying value of these assets in relation to the operating performance of the business and future undiscounted cash flows expected to result from the use of these assets. No such impairments have been recognized during the years ended December 31, 2012, 2013 or 2014.
	Revenue Recognition
	The Company recognizes revenue in accordance with the FASB Accounting Standards Codification 605, Revenue Recognition, or ASC 605. The Company recognizes revenue when the following criteria are met: persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured.
	The Company has entered into license agreements with collaborators. The terms of these agreements have included nonrefundable signing and licensing fees, as well as milestone payments and royalties on any future product sales developed by the collaborators under such licenses. The Company assesses these multiple elements in accordance with ASC 605, to determine whether particular components of the arrangement represent separate units of accounting.
	These collaboration agreements will be accounted for in accordance with Accounting Standards Update, or ASU, No. 2009-13, Topic 605 – Multiple-Deliverable Revenue Arrangements, or ASU 2009-13. This guidance requires the application of the “relative selling price” method when allocating revenue in a multiple deliverable arrangement. The selling price for each deliverable shall be determined using vendor specific objective evidence of selling price, if it exists; otherwise, third-party evidence of selling price shall be used. If neither exists for a deliverable, the vendor shall use its best estimate of the selling price for that deliverable. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license has standalone value and the fair value of the undelivered performance obligations can be determined. If the fair value of the undelivered performance obligations can be determined, such obligations are accounted for separately as the obligations are fulfilled. If the license is considered to either not have stand-alone value or have stand-alone value but the fair value of any of the undelivered performance obligations cannot be determined, the arrangement is accounted for as a single unit of accounting and the license payments and payments for performance obligations are recognized as revenue over the estimated period of when the performance obligations are performed.
	When the Company determines that an arrangement should be accounted for as a single unit of accounting, the Company must determine the period over which the performance obligations will be performed and revenue will be recognized, to the extent this is determinable. If the timing and the level of effort to complete performance obligations under the arrangement is not estimable, then the Company recognizes revenue under the arrangement on a straight-line basis over the period that the Company expects to complete such performance obligations.
	The Company’s license agreements with Pharmstandard International S.A. (“Pharmstandard”), Medinet Co., Ltd. (“Medinet”) and Green Cross Corp. (“Green Cross”) contain, and other agreements it enters into may also contain, milestone payments. Revenues from milestones, if they are non-refundable and considered substantive, are recognized upon successful accomplishment of the milestones. If not considered substantive, milestones are initially deferred and recognized over the remaining performance obligation.
	The Company’s current license agreements with Pharmstandard, Medinet and Green Cross and any future license agreements the Company may enter into may provide for royalty payments. Royalty revenue is recognized upon the sale of the related products, provided there are no remaining performance obligations under the arrangement. To date, the Company has not received any royalty payments.
	The Company conducted AGS-004 a phase 2b clinical trial of AGS-004 that was funded entirely by the National Institutes of Health (“NIH”) and National Institute of Allergy and Infectious Diseases (“NIAID”). Under the NIH and NIAID agreement, as amended, the Company is entitled to receive reimbursement of its direct expenses and allocated overhead and general and administrative expenses of up to $38.4 million and payment of other specified amounts totaling up to $1.4 million upon its achievement of specified development milestones. These reimbursable expenses and allocated overhead are directly related to the development of novel HIV immunotherapy candidates and are recognized as revenue based on the reimbursable expenses that have accrued in accordance with the contractual terms in the arrangement. The Company recognizes revenues from the achievement of milestones under the NIH contract upon the accomplishment of any such milestone.
	Income Taxes
	The Company provides for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	Segment and Geographic Information
	Operating segments are defined as components of an enterprise engaging in business activities from which it may earn revenues and incur expenses, for which discrete financial information is available and whose operating results are regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and all of the Company operations are in North America.
	Research and Development
	Research and development costs include all direct costs related to the development of the Company’s technology, including salaries and related benefits of research and development (“R&D”) personnel, depreciation of laboratory equipment, fees paid to consultants and contract research organizations, stock-based compensation for R&D personnel, sponsored research payments and license fees. R&D costs are expensed as incurred.
	Redeemable Convertible Preferred Stock
	The carrying value of redeemable convertible preferred stock is increased by periodic accretions so that the carrying amount will equal the redemption amount as of the redemption date. These increases were recorded through charges against additional paid-in capital, to the extent it was available, or the accumulated deficit.
	Warrant Liability
	Warrants to purchase the Company’s convertible preferred stock were classified as liabilities and recorded at their estimated fair value. In each reporting period, any change in fair value of the freestanding warrants are recorded as expense in the case of an increase in fair value and income in the case of a decrease in fair value.
	Other Receivables
	The Company has recorded other receivables of $424,501 and $129,019 as of December 31, 2013 and 2014. These receivables are primarily related to amounts due under the NIH contract as of such dates. The Company assesses the recoverability of other receivables as of each balance sheet date.
	Stock-Based Compensation
	The Company estimates the grant date fair value of its share-based awards and amortizes this fair value to compensation expense over the requisite service period or vesting term (see Note 12).
	Investment Tax Credits
	Other income of $694,331, $0 and $140,556 was recognized during the years ended December 31, 2012, 2013 and 2014, respectively, for scientific research and experimental development (“SR&ED”) investment tax credits in Canada. Under Canadian and Ontario law, the Company’s Canadian subsidiary is entitled to SR&ED. Because these credits are subject to a claims review, the Company recognizes such credits when received.
	Comprehensive Income (Loss)
	ASC 220, Comprehensive Income, establishes standards for reporting and display of comprehensive income and its components in a full set of financial statements. The Company’s other comprehensive income (loss) is related to foreign currency translation adjustments and unrealized gain (loss) on short-term investments.
	Foreign Currency Translation
	Gains and losses from foreign currency transactions are reflected in income currently.
	The Company has identified the functional currency of its subsidiaries with foreign operations as the applicable local currency. The translation from the applicable local currency to United States dollars is performed using the exchange rate in effect as of the balance sheet date. Revenue and expense accounts are translated using the average exchange rate experienced during the period. Adjustments resulting from the translation of the Company’s subsidiaries’ financial statements from its functional currency to the United States dollar are not included in determining net loss, but are reported as accumulated other comprehensive gain (loss), a separate component of stockholders’ (deficit) equity.
	Derivatives
	The Company issued a put option to exchange certain shareholders’ stock in DC Bio for stock in the Company (see Note 5). Derivatives are recorded in the balance sheet at fair value as of each balance sheet date utilizing pricing models for nonexchange traded contracts (see Note 9). The Company does not use derivative financial instruments for speculative purposes. As of December 31, 2013 and 2014, there were no derivatives outstanding.
	Interest Expense
	During the year ended December 31, 2014, interest expense primarily resulted from accrued interest on our note payable to Medinet, which was issued in December 2013, and interest from a venture loan and security agreement entered into in September 2014 with two financial institutions (see Note 8).
	Recently Issued Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued a new accounting standard update pertaining to disclosures for development stage entities. The new guidance eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The new standard is effective prospectively for annual reporting beginning after December 15, 2014, and interim periods within those annual periods, but early adoption is permitted. The Company adopted this new accounting standard during the three months ended June 30, 2014.
	In May 2014, the FASB issued a new accounting standard update pertaining to accounting for revenue from contracts with customers. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.
	In August 2014, the FASB issued a new standard update that specifies the responsibility that an entity’s management has to evaluate whether there is substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for interim and annual periods beginning after December 15, 2016, and is not expected to have an effect on the Company’s financial statements.
	In July 2013, the FASB issued a new accounting standard update on the financial statement presentation of unrecognized tax benefits. The new guidance provides that a liability related to an unrecognized tax benefit would be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. The new guidance became effective for the Company on January 1, 2014 and it was applied prospectively to unrecognized tax benefits that existed as of the effective date with retrospective application permitted. This updated standard did not have a material impact on the Company’s condensed consolidated financial statements.

Note_3_Fair_Value_of_Financial

Note 3 - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	3. Fair Value of Financial Instruments
	The estimated fair values of all of the Company’s financial instruments, excluding long-term debt, approximate their carrying amounts in the Consolidated Balance Sheets as of December 31, 2013 and 2014.
	As of December 31, 2013 and December 31, 2014, the Company held certain assets that are required to be measured at fair value on a recurring basis. These assets include money market funds included in cash equivalents and short-term investments in corporate debt securities. The valuation of these financial instruments uses a three tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.
	The Company’s Level 1 assets consist of money-market funds and the method used to estimate the fair value of the Level 1 assets is based on observable market data as these money-market funds are publicly-traded. The Company’s Level 2 assets consist of short-term debt instruments in corporate debt securities valued using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. As of each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.
	As of December 31, 2013 and December 31, 2014, these financial instruments and respective fair values have been classified as follows:
		Quoted Prices		Significant			Significant			Balance as of
		in Active		Other			Unobservable			December 31,
		Markets for		Observable			Inputs			2013
		Identical Assets		Inputs			(Level 3)
		(Level 1)		(Level 2)
	Assets
	Money-market funds	$	22,891,418	$	—		$	—		$	22,891,418
	Corporate debt securities – short-term		—		13,659,812			—			13,659,812
	Total assets at fair value	$	22,891,418	$	13,659,812		$	—		$	36,551,230
		Quoted Prices		Significant			Significant			Balance as of
		in Active		Other			Unobservable			December 31,
		Markets for		Observable			Inputs			2014
		Identical Assets		Inputs			(Level 3)
		(Level 1)		(Level 2)
	Assets
	Money-market funds	$	35,541,595	$	—		$	—		$	35,541,595
	Corporate debt securities – short-term		—		20,266,243			—			20,266,243
	Restricted cash – long-term		1,325,000								1,325,000
	Total assets at fair value	$	36,866,595	$	20,266,243		$	—		$	57,132,838
	During the years ended December 31, 2013 and 2014, there were no transfers between Levels 1 and 2 assets.
	The changes in the balance of Level 3 liabilities for the year ended December 31, 2013 were as follows:
		Fair Value Measurements Using Significant Unobservable
		Inputs (Level 3)
		Beginning		Net Change in			Reduction			Ending
		Balance		Unrealized						Balance
				(Gains) Losses
	Warrant Liability	$	6,392,652	$	(355,352	)	$	(6,037,300	)	$	—
		$	6,392,652	$	(355,352	)	$	(6,037,300	)	$	—
	During the year ended December 31, 2013, all outstanding warrants to purchase preferred stock were cancelled. As a result, there were no warrants to purchase preferred stock outstanding as of December 31, 2013 or 2014, and there were no Level 3 assets or liabilities outstanding during the year ended December 31, 2014.
	The fair value of the Company’s long-term debt was derived by evaluating the nature and terms of each note, considering the prevailing economic and market conditions as of each balance sheet date and based on the Level 2 valuation hierarchy of the fair value measurements standard using a present value methodology. The fair value of the Company’s long-term debt as of December 31, 2013 approximated its carrying value of $7.0 million. The fair value of the Company’s long-term debt as of December 31, 2014 was approximately $19.4 million compared with its carrying value of $19.8 million.

Note_4_Property_and_Equipment

Note 4 - Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment
	Property and equipment consist of the following:
		Useful Life		31-Dec-13			31-Dec-14
		(Years)
	Office furniture and equipment	7		$	528,732		$	458,380
	Computer equipment	3			712,609			788,563
	Computer software	3			540,809			629,948
	Laboratory equipment	7			5,264,952			5,345,786
	Leasehold improvements	5			2,643,023			2,646,891
	Asset related to facility lease obligation				—			3,380,223
	Construction of manufacturing facility in progress				76,010			500,093
					9,766,135			13,749,884
	Less: Accumulated depreciation and amortization				(8,164,032	)		(8,236,329	)
	Property and equipment, net			$	1,602,103		$	5,513,555
	Assets related to the Company’s facility lease obligation and construction of manufacturing facility in progress were primarily recognized during the year ended December 31, 2014 due to the Company deemed to be the accounting owner of the facility during its construction period under build-to-suite lease accounting (see Note 16).
	Depreciation and amortization expense was as follows:
	Year ended December 31, 2012	$	505,261
	Year ended December 31, 2013		611,421
	Year ended December 31, 2014		566,117

Note_5_Noncontrolling_Interest

Note 5 - Noncontrolling Interest	12 Months Ended
	Dec. 31, 2014
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	5. Noncontrolling Interest
	Prior to October 2012, the Company owned 49.94% of the total capital stock of DC Bio. As of December 31, 2011, the other shareholders’ ownership interests in DC Bio were represented on the consolidated balance sheet by noncontrolling interest as a separate component of stockholders’ (deficit) equity. In October 2012 and December 2012, DC Bio repurchased the noncontrolling interests from these shareholders. Subsequent to these transactions, the Company owned 100% of DC Bio and eliminated its equity attributable to non-controlling interest through additional paid-in capital.

Note_6_Income_Taxes

Note 6 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	6. Income Taxes
	No provision for U.S. federal, state or foreign income taxes has been recorded as the Company has incurred net operating losses since its inception in 1997.
	Significant components of the Company’s deferred tax assets and liabilities consist of the following:
		December 31,
		2013			2014
	U.S. federal and state net operating loss carryforwards	$	41,359,722		$	59,689,264
	Foreign net operating loss carryforwards		1,827,221			1,743,603
	Contribution carryforwards		3,055			4,245
	Research and development credits		4,061,844			5,253,055
	Investment tax credits		38,175			35,108
	Stock-based compensation		22,282			462,796
	Patents and other intangibles		2,967			611
	Other accruals		97,157			125,614
	Deferred revenue		—			372,040
	Property and equipment		532,316			510,466
	Total deferred tax assets		47,944,739			68,196,802
	Valuation allowance for deferred assets		(47,944,739	)		(68,196,802	)
	Net deferred tax assets	$	—		$	—
	As of December 31, 2013 and 2014, the Company provided a full valuation allowance against its net deferred tax assets since as of that time, the Company could not assert that it was more likely than not that these deferred tax assets would be realized. There was an increase in the valuation allowance in the year ended December 31, 2014 of $20,252,063, all of which was allocable to current operating activities.
	As of December 31, 2014, the Company had U.S. federal and state, and Canadian federal and provincial net operating loss carryforwards of approximately $158,406,400, $176,699,700, $6,579,600, and $6,579,600, respectively. These net operating loss carryforwards begin to expire in 2018, 2017, 2015 and 2015, respectively. As of December 31, 2014, the Company had U.S. federal and state tax credit carryforwards of approximately $5,028,400 and $340,400, respectively. These credit carryforwards begin to expire in 2020 and 2019, respectively. As of December 31, 2014, the Company had Canadian investment tax credit carryforwards of approximately $35,100 that begin to expire in 2024. The utilization of the net operating loss and tax credit carryforwards may be subject to limitation under the rules regarding a change in stock ownership as determined by the Internal Revenue Code, and state and foreign tax laws. Section 382 of the Internal Revenue Code of 1986, as amended, imposes annual limitations on the utilization of net operating loss (“NOL”) carryforwards, other tax carryforwards, and certain built-in losses upon an ownership change as defined under that section. In general terms, an ownership change may result from transactions that increase the aggregate ownership of certain stockholders in the Company’s stock by more than 50 percentage points over a three year testing period. If the Company has undergone a Section 382 ownership change, an annual limitation would be imposed on certain of the Company’s tax attributes, including NOL and capital loss carryforwards, and certain other losses, credits, deductions or tax basis. As of December 31, 2014, the Company has not completed a formal study to determine whether there are 382 limitations that apply.
	As of December 31, 2014, the Company had no foreign unremitted earnings from DC Bio, its Canadian subsidiary.
	Taxes computed at the statutory U.S. federal income tax rate of 34.0% are reconciled to the provision for income taxes for the years ended December 31, 2012, 2013 and 2014 as follows:
		December 31,						December 31,						December 31,
		2011						2012						2014
		Amount			Percent of			Amount			Percent of			Amount			Percent of
					Pretax						Pretax						Pretax
					Earnings						Earnings						Earnings
	U.S. federal tax statutory rate	$	(3,560,252	)		34	%	$	(8,133,331	)		34	%	$	(18,124,019	)		34	%
	State taxes (net of federal benefit)		(476,446	)		4.5	%		(789,412	)		3.3	%		(1,707,912	)		3.2	%
	U.S. federal research and development tax credits		—			0	%		(1,262,562	)		5.3	%		(1,701,727	)		3.2	%
	Nondeductible interest expense		(1,782,830	)		17	%		(132,546	)		0.6	%		—			0	%
	Other nondeductible expenses		(210,790	)		2	%		419,934			(1.8	%)		658,740			(1.1	%)
	Expiration of capital loss carryforward		3,246,049			(31.0	%)		—			(0.0	%)		—			0	%
	Increase in unrecognized tax benefits		—			0	%		378,769			(1.6	%)		510,516			(1.0	%)
	Change in effective state tax rate		—			0	%		1,349,062			(5.6	%)		1,685			(0.0	%)
	Expiration of NOL & contribution carryforwards		57,538			(0.5	%)		6,630			(0.0	%)		77,391			(0.1	%)
	Change in valuation reserves		2,618,552			(25.2	%)		8,811,127			(36.8	%)		20,252,063			(38.1	%)
	Deferred tax asset true-ups		108,179			(0.8	%)		(647,671	)		2.6	%		33,263			(0.1	%)
	Provision for income taxes	$	—			0	%	$	—			0	%	$	—			0	%
	The research and development credit, which had previously expired on December 31, 2011, was reinstated as part of the American Taxpayer Relief Act of 2012 enacted on January 2, 2013. This legislation retroactively reinstated and extended the credit from the previous expiration date through December 31, 2013. As a result, the Company adjusted its deferred tax assets in 2013 for the 2012 and 2013 research and development credits, net of the gross unrecognized tax benefit, which resulted in an increase to the deferred tax assets and a corresponding increase to the valuation allowance of approximately $298,000 and $585,700, respectively.
	On July 23, 2013, the State of North Carolina enacted House Bill 998, which reduced the corporate income tax rate from 6.9% in 2013 to 6% in 2014 and to 5% in 2015. As a result of the new enacted tax rate, the Company adjusted its deferred tax assets in 2013 by applying the lower rate, which resulted in a decrease to the deferred tax assets and a corresponding decrease to the valuation allowance of approximately $1,349,100.
	The Company had gross unrecognized tax benefits of approximately $1,644,000 as of January 1, 2014. As of December 31, 2014, the total gross unrecognized tax benefits were approximately $2,155,000 and of this total, none would affect the Company’s effective tax rate if recognized. The Company does not anticipate a significant change in total unrecognized tax benefits or the Company’s effective tax rate due to the settlement of audits or the expiration of statutes of limitations within the next 12 months.
	The Company’s policy is to recognize interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2013 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions.
	The Company has analyzed its filing positions in all significant federal and state jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is no longer subject to United States federal, state, and local tax examinations by tax authorities for years before 2011 although carryforward attributes that were generated prior to 2011 may still be adjusted upon examination by the Internal Revenue Service if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.
	The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions during the years ended December 31, 2012, 2013 and 2014:
		2012			2013			2014
	Beginning balance	$	1,272,800		$	1,265,700		$	1,644,500
	Gross increase for tax positions related to current periods		—			378,800			474,300
	Gross (decrease) increase for tax positions related to prior periods		(7,100	)		—			36,200
	Ending balance	$	1,265,700		$	1,644,500		$	2,155,000

Note_7_Convertible_Term_Notes

Note 7 - Convertible Term Notes	12 Months Ended
	Dec. 31, 2014
Convertible Debt [Abstract]
Convertible Debt [Text Block]	7. Convertible Term Notes
	On September 9, 2010, the Company entered into a convertible note and warrant purchase agreement with a group of existing preferred stockholders, which provided for a total of up to $6,000,000 in borrowings by the Company. On September 9, 2010 and December 15, 2010, the Company received the proceeds under the agreement in two separate tranches of $4,872,066 and $1,127,925, respectively. The convertible notes issued pursuant to the agreement bore interest at a rate of 10% and provided for conversion into series C preferred stock of the Company. The note purchasers were also issued warrants to purchase series C preferred stock of the Company (Note 11). The proceeds from the convertible notes were allocated among the notes and the associated warrants based on the fair value of the warrants with the residual balance assigned to the convertible notes. The Company increased the value assigned to the convertible notes through interest expense using the effective interest method such that the value of the convertible notes will equal the accrued principal and interest of $6,603,333 as of maturity. The Company recognized $193,402 of interest expense related to the convertible notes during the years ended December 31, 2012.
	On July 27, 2011, the Company entered into a convertible note and warrant purchase agreement with a group of existing preferred stockholders, which provided for a total of up to $3,500,000 in borrowings by the Company. On July 27, 2011, the Company received the proceeds under the agreement of $3,500,000. The convertible notes bore interest at a rate of 10% and provided for conversion into series C preferred stock of the Company. The note purchasers were also issued warrants to purchase series C preferred stock of the Company (Note 11). The proceeds from the convertible notes were allocated among the notes and the associated warrants based on the fair value of the warrants with the residual balance assigned to the convertible notes. The Company increased the value assigned to the convertible notes through interest expense using the effective interest method such that the value of the convertible notes will equal the accrued principal and interest of $3,686,250 as of maturity. The Company recognized $98,662 of interest expense related to the July 2011 convertible notes during the years ended December 31, 2012.
	In December 2011, the Company and the holders of the 2010 convertible notes and the July 2011 convertible notes agreed to extend the maturity dates of the notes to March 31, 2012. The Company did not record any gain or loss in connection with the extension of the maturity date of the notes because it determined that the extension of the maturity date of the notes met the criteria of a troubled debt restructuring outlined in ASC Topic 470-60, Troubled Debt Restructurings. The Company recognized $292,064 of interest expense related to the 2010 convertible notes and the July 2011 convertible notes during the year ended December 31, 2012.
	On April 10, 2012, the principal and interest on the convertible term notes totaling $10,668,185 converted into an aggregate of 3,023,661 shares of series D preferred stock of the Company (see Note 10).

Note_8_Notes_Payable

Note 8 - Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8. Notes Payable
	Notes payable consist of the following:
		December 31,			December 31,
		2013			2014
	Notes payable under the venture loan and security agreement	$	—		$	12,500,000
	Less related debt discount		—			(373,756	)
	Notes payable under the venture loan and security agreement, net of debt discount		—			12,126,244
	Promissory note payable to Medinet including accrued interest		6,936,466			7,623,546
	Other notes payable		123,087			77,640
	Total notes payable		7,059,553			19,827,430
	Less current portion		(45,447	)		(30,885	)
	Long-term portion of notes payable	$	7,014,106		$	19,796,545
	On September 29, 2014, the Company entered into a venture loan and security agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Fortress Credit Co LLC (together, the “Lenders”) under which the Company may borrow up to $25.0 million in two tranches of $12.5 million each (the “Loan Facility”).
	The Company borrowed the first tranche of $12.5 million upon the closing of the transaction on September 29, 2014.  Subject to certain other funding conditions, the second tranche of $12.5 million will be available for drawdown at any time commencing on the date the Company completes the enrollment and randomization of patients in the Company’s phase 3 clinical trial of AGS-003 and continuing until September 30, 2015.  The per annum interest rate for each tranche will be a floating rate equal to 9.25% plus the amount by which the one-month London Interbank Offered Rate (“LIBOR”) exceeds 0.50% (effectively a floating rate equal to 8.75% plus the one-month LIBOR Rate).  The total per annum interest rate shall not exceed 10.75%.
	The Company incurred $449,796 for costs in connection with the closing of the Loan Agreement. These costs were capitalized as deferred financing costs and amortized to interest expense over the terms of the related debt.
	The Company has agreed to repay the first tranche of $12.5 million on an interest only basis monthly until September 30, 2016, followed by monthly payments of principal and accrued interest through the scheduled maturity date for the first tranche loan on September 30, 2018. In addition, a final payment for the first tranche loan equal to $625,000 will be due on September 30, 2018, or such earlier date specified in the Loan Agreement.  The Company has agreed to repay any amounts advanced under the second tranche of $12.5 million in 18 monthly payments of interest only followed by 24 monthly payments of principal and accrued interest through the scheduled maturity date for the second tranche loan, which is 42 months following the date the Company draws down the second tranche loan.  In addition, a final payment equal to 5.0% of the amount drawn down under the second tranche loan will be due on the scheduled maturity date for such loan, or such earlier date specified in the Loan Agreement.  In addition, if the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the Lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance, equal to 3% if the prepayment occurs on or before 24 months after the funding date, 2% if the prepayment occurs more than 24 months after, but on or before 36 months after, the funding date thereof, or 1% if the prepayment occurs more than 36 months after the funding date thereof.
	The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company also has agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions.
	The Loan Agreement includes customary affirmative and restrictive covenants, but does not include any covenants to attain or maintain certain financial metrics, and also includes customary events of default, including payment defaults, breaches of covenants, change of control and a material adverse change default.  Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
	In connection with the Loan Agreement, the Company issued to the Lenders and their affiliates warrants to purchase a total of 82,780 shares of Common Stock at a per share exercise price of $9.06 (the “Warrants”).  The Lenders may not exercise the warrants for more than 41,390 of such shares of Common Stock until the earliest to occur of (i) a merger or consolidation of the Company, or a sale of all or substantially all of its assets, (ii) the Company’s satisfaction of the conditions precedent to the making of the second tranche loan, and (iii) the funding of the second tranche loan.  The Warrants will terminate on September 29, 2021 or such earlier date as specified in the Warrants.  The Company recorded a debt discount of $338,673 equal to the value of these warrants.  This debt discount is offset against the note payable balance and included in additional paid-in capital on the Company's balance sheet.
	In December 2013, in connection with the license agreement with Medinet, as described in Note 9, the Company borrowed $9.0 million pursuant to an unsecured promissory note that bears interest at a rate of 3.0% per annum. The principal and interest under the note are due and payable on December 31, 2018. Under the terms of the note and the license agreement, any milestone payments related to the developmental and regulatory milestones that become due will be applied first to the repayment of the loan. The Company has the right to prepay the loan at any time. If the Company has not repaid the loan by December 31, 2018, then the Company has agreed to grant to Medinet a non-exclusive, royalty-bearing license to make and sell Arcelis products in Japan for the treatment of cancer. In such event, the amounts owing under the loan as of December 18, 2018 may constitute pre-paid royalties under the license or would be due and payable. Royalties under this license would be paid until the expiration of the licensed patent rights in Japan at a rate to be negotiated. If the Company and Medinet cannot agree on the royalty rate, they have agreed to submit the matter to arbitration. Because the $9.0 million promissory note was issued at a below market interest rate, the Company allocated the proceeds of the loan between the license agreement and the debt at the time of issuance. Accordingly, as of December 31, 2013, the Company recorded $6.9 million to notes payable, based upon an effective interest rate of 8.0%, and $2.1 million as a deferred liability. As of December 31, 2014, the Company recorded $7.6 million to notes payable, including $0.7 million accrued interest recorded during the year ended December 31, 2014. The total deferred liability was $3.1 million as of December 31, 2014 including the $1.0 million received by the Company for a manufacturing license (see Note 10).
	The Company entered into a Master Lease Agreement in July 2012 with a lending institution, which provides for the Company to borrow funds up to $100,000 to finance computer equipment. Through December 31, 2014, the Company has borrowed $95,756 under this agreement, of which $48,429 and $16,356 was outstanding as of December 31, 2013 and December 31, 2014, respectively. Borrowings are collateralized by substantially all of the computer equipment financed under the agreement, bear interest at a rate of 0.98% per annum and are to be repaid in 36 equal monthly installments commencing on the date of borrowing.
	During November 2013, the Company borrowed $77,832 from a lending institution to finance the purchase of additional computer equipment, of which $74,658 and $61,284 in principal was outstanding as of December 31, 2013 and December 31, 2014, respectively. Borrowings are collateralized by substantially all of the computer equipment financed under the agreement, bear interest at a rate of 8.31% per annum and are to be repaid in 60 equal monthly installments commencing on the date of borrowing.

Note_9_Derivatives

Note 9 - Derivatives	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	9. Derivatives
	In conjunction with the DC Bio transaction on December 7, 2004 (see Note 5), the Company issued a put option whereby in the event DC Bio has not been acquired or had not completed an initial public offering by December 7, 2007, the other shareholders of DC Bio would have the right to put their DC Bio Class A preferred shares and Class B preferred shares to the Company for shares of the Company’s stock. As of December 31, 2011, the Company had reserved 652,608 shares of series C preferred stock, 419,768 shares of series B preferred stock and 23,703 shares of its common stock for issuance upon the exchange of Class A and Class B preferred shares of DC Bio should such put option be exercised. The Company recorded a liability of $1,036,403 as of December 31, 2011 based on the fair market value of the put option, which was calculated based on the fair market value of the Company’s stock issuable upon exercise of the put option, less the fair market value of the DC Bio shares held by such shareholders, as described above. For purposes of this calculation, the Company determined that the fair market value of the Company’s stock issuable upon exercise of the put option was $1,487,668 as of December 31, 2011 and that the fair market value of the DC Bio shares was $451,265 as of December 31, 2011. The value of the DC Bio shares held by the other shareholders was valued under the income approach utilizing a discounted cash flow model. The discount rate reflects the risk in the cash flows. The change in fair value of the put was recorded as derivative (expense) income. The Company terminated the put option in October 2012 when DC Bio repurchased the noncontrolling interests for a total of approximately $180,000.

Note_10_Common_Stock_Redeemabl

Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock
	As of December 31, 2013 and 2014, the Company was authorized to issue 120,000,000 and 200,000,000 shares of common stock, 160,700,000 and 0 shares of redeemable convertible preferred stock, 0 and 5,000,000 shares of preferred stock, respectively.
	In February 2014, the Company issued and sold 6,228,725 shares of its common stock, including 603,725 shares of common stock sold pursuant to the underwriters’ exercise of their option to purchase additional shares, in the Company’s initial public offering, at a public offering price of $8.00 per share, for aggregate gross proceeds of $49.8 million. The net offering proceeds to the Company, after deducting underwriting discounts and commissions of approximately $3.5 million and offering expenses of approximately $2.9 million, were approximately $43.4 million. Upon the closing of the initial public offering, all of the then-outstanding shares of the Company’s redeemable convertible preferred stock automatically converted into 13,188,251 shares of common stock. Accordingly, as of December 31, 2014, the Company has no redeemable convertible preferred stock outstanding and no shares of preferred stock have been issued since their authorization in 2014.
	Redeemable Convertible Preferred Stock
	In April 2012, the Company sold shares of its series D preferred stock in a private placement to certain of its existing holders of preferred stock and additional accredited investors for an aggregate purchase price of $19.7 million. Included in this amount was $10.7 million of outstanding principal and interest on various convertible notes which converted to series D preferred stock in this financing.
	In August 2012, the Company sold 3,716,935 shares of its series D-1 preferred stock in a private placement to certain of its existing holders of preferred stock and other accredited investors for $4.298725 per share for an aggregate purchase price of $16.0 million.
	In July 2013, all 7,433,870 shares of series D-1 preferred stock outstanding were exchanged for 16,151,212 shares of series D preferred stock. In addition, in connection with the exchange, the liquidation preference and the redemption price of the series D preferred stock were reduced to $1.978565 per share. As a result of the reduction in the liquidation preference of the series D preferred stock, the Company issued an aggregate of 6,373,782 additional shares of series D preferred stock to the holders that had purchased shares of series D preferred stock prior to such reduction for no additional consideration.
	The Company recorded the reduction to liquidation preference as a reversal to prior accretion taken on each series of preferred stock impacted, which reduced net loss attributable to common stockholders in the earnings per share calculation (see Note 19). The Company recorded any remaining reduction in liquidation preference as an increase to additional paid-in capital. In addition, the Company recorded the fair value of the incremental series D preferred stock shares issued in these exchanges in additional paid-in capital as a preferred stock dividend, which increased net loss attributable to common stockholders in the earnings per share calculation (see Note 19).
	In August 2013, the Company sold 16,898,436 shares of series E preferred stock for an aggregate purchase price of $22,007,404.
	In October 2013 and November 2013, the Company sold 921,423 shares of its series E preferred stock for an aggregate purchase price of $1,200,000 and 19,037,063 shares of its series E preferred stock for an aggregate purchase price of $24,792,595, respectively.
	In connection with the issuance and sale of series E preferred stock, in December 2013, the Company issued a warrant to purchase 9,598 shares of its common stock, at an exercise price of $6.60 per share, to a placement agent.
	Upon the closing of the Company’s initial public offering, all of the outstanding shares of redeemable convertible preferred stock automatically converted into 13,188,251 shares of the Company’s common stock.
	The table below represents a rollforward of the redeemable convertible preferred stock:
		Series A Preferred						Series B Preferred						Series B-1						Series C Preferred						Series D Preferred						Series D-1 Preferred						Series E Preferred
														Preferred
		Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount
	Balance as of December 31, 2011		1,276,103		$	1,276,103			24,326,574		$	42,814,762			917,771		$	1,615,276			112,165,271		$	32,016,165			—		$	—			—		$	—			—		$	—
	Issuance of shares		—			—			—			—			—			—			—			—			2,549,897			4,793,806			3,713,333			7,842,733			—			—
	Conversion of bridge note		—			—			—			—			—			—			—			—			3,023,661			5,684,483			—			—			—			—
	Conversion of accrued services		—			—			—			—			—			—			—			—			7,142			25,200			3,602			15,485			—			—
	Pull through of existing preferred		—			—			(3,652,680	)		(6,428,717	)		—			—			(64,256,463	)		(18,571,283	)		2,557,039			4,807,233			3,716,935			7,835,133			—			—
	Stock issuance costs		—			—			—			—			—			—			—			—			—			(128,275	)		—			(80,659	)		—			—
	Shares converted to common		(124,050	)		(124,050	)		(2,182,576	)		(3,841,332	)		(917,771	)		(1,615,276	)		(8,605,955	)		(2,487,276	)		—			—			—			—			—			—
	Accretion		—			—			—			—			—			—			—			327,465			—			18,529			—			5,377			—			—
	Balance as of December 31, 2012		1,152,053			1,152,053			18,491,318			32,544,713			—			—			39,302,853			11,285,071			8,137,739			15,200,976			7,433,870			15,618,069			—			—
	Exchange of Series D-1		—			—			—			—			—			—			—			—			16,151,212			26,887,407			(7,433,870	)		(15,628,821	)		—			—
	Issuance of shares		—			—			—			—			—			—			—			—			6,373,782			11,446,143			—			—			36,856,922			47,409,867
	Exchange of Series D		—			—			—			—			—			—			—			—			(12,607,779	)		(24,945,326	)		—			—			19,154,336			24,945,326
	Pull through of existing preferred		(111,837	)		(35,788	)		(8,687,630	)		(4,892,873	)		—			—			(10,586,174	)		(979,070	)		2,985,863			4,030,920			—			—			—			—
	Reduction of liquidation value		—			(783,396	)		—			(18,001,661	)		—			—			—			(6,195,373	)		—			—			—			—			—			—
	Stock issuance costs		—			—			—			—			—			—			—			—			—			(64,530	)		—			—			—			(556,247	)
	Reversal of prior accretion		—			—			—			(4,128,742	)		—			—			—			(1,528,896	)		—			—			—			—			—			—
	Accretion		—			—			—			—			—			—			—			74,152			—			706,902			—			10,752			—			92,841
	Balance as of December 31, 2013		1,040,216			332,869			9,803,688			5,521,437			—			—			28,716,679			2,655,884			21,040,817			33,262,492			—			—			56,011,258			71,891,787
	Accretion		—			—			—			—			—			—			—			—			—			336,350			—			—			—			526,876
	Shares converted to common stock		(1,040,216	)		(332,869	)		(9,803,688	)		(5,521,437	)		—			—			(28,716,679	)		(2,655,884	)		(21,040,817	)		(33,598,842	)		—			—			(56,011,258	)		(72,418,423	)
	Stock issuance costs		—			—			—			—			—			—			—			—			—			—			—			—			—			(240	)
	Balance as of December 31, 2014		—		$	—			—		$	—			—		$	—			—		$	—			—		$	—			—		$	—			—		$	—

Note_11_Warrants

Note 11 - Warrants	12 Months Ended
	Dec. 31, 2014
Warrants [Abstract]
Warrants [Text Block]	11. Warrants
	In connection with the issuance and sale of series E preferred stock, in December 2013, the Company issued a warrant to purchase 9,598 shares of its common stock, at an exercise price of $6.60 per share, to a placement agent. During the year ended December 31, 2014, warrants to purchase 9,598 shares of the Company’s common stock at $6.60 per share were settled in a cashless exercise for 1,679 shares of common stock in conjunction with the closing of the Company’s initial public offering in February 2014.
	As discussed in Note 8 regarding the Company’s notes payable, in connection with the Company’s Loan Agreement signed in September 2014, the Company issued warrants to purchase a total of 82,780 shares of Common Stock at a per share exercise price of $9.06.  The warrants may not be exercised for more than 41,390 of such shares of Common Stock until the earliest to occur of (i) a merger or consolidation of the Company, or a sale of all or substantially all of its assets, (ii) the Company’s satisfaction of the conditions precedent to the making of the second tranche loan, and (iii) the funding of the second tranche loan.  The warrants will terminate on the earlier of September 29, 2021 or such earlier date as specified in the warrants.
	In conjunction with entering into a loan agreement with a bank in December 2000, the Company issued warrants to purchase shares of its common stock, all of which expired as of December 31, 2012, except for one warrant. This warrant to purchase one share of the Company’s common stock, at an exercise price of $23,894.34 per share, remained outstanding as of December 31, 2013 and 2014.
	Outstanding warrants to purchase the Company’s common stock as of December 31, 2013 were as follows. There were no warrants to purchase preferred stock as of December 31, 2013.
	Type of Warrant	Number of Shares		Exercise Price		Expiration
						Date(s)
	Common		1	$	23,894.34	7/13/16
	Common		9,598	$	6.6	12/20/23
	Outstanding warrants to purchase the Company’s common stock as of December 31, 2014 were as follows. There were no warrants to purchase preferred stock as of December 31, 2014.
	Type of Warrant	Number of Shares		Exercise Price		Expiration
						Date(s)
	Common stock		1	$	23,894.34	7/13/16
	Common stock		82,780	$	9.06	9/29/21
	In November 2013, the Company entered into an agreement with Pharmstandard under which Pharmstandard purchased additional shares of the Company’s series E preferred stock. Upon the closing of the Company’s initial public offering, all of the outstanding shares of redeemable convertible preferred stock automatically converted into 13,188,251 shares of the Company’s common stock.  Under this agreement, the Company agreed to enter into a manufacturing rights agreement for the European market with Pharmstandard and that the manufacturing rights agreement would provide for the issuance of warrants to Pharmstandard to purchase 499,788 shares of the Company’s common stock at an exercise price of $5.82 per share. As of March 31, 2015, the Company had not entered into this manufacturing rights agreement or issued the warrants.

Note_12_Stock_Options_and_Empl

Note 12 - Stock Options and Employee Stock Purchase Plan	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12. Stock Options and Employee Stock Purchase Plan
	In January 2014, the Company’s board of directors and stockholders approved, effective upon the closing of the Company’s initial public offering, the 2014 Stock Incentive Plan (the “2014 Plan”). Under the 2014 Plan, the Company may grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards for the purchase of that number of shares of Common Stock equal to the sum of 1,951,182 shares, plus such number of shares, up to 357,841 shares, as is equal to the sum of the number of shares reserved for issuance under the Company’s 2008 Stock Incentive Plan (the “2008 Plan”) that remained available for grant under the 2008 Plan immediately prior to the closing of the Company’s initial public offering on February 12, 2014 (381,250 shares) and the number of shares subject to outstanding awards under the 2008 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right, plus an annual increase, to be added on the first day of the 2015 fiscal year and each subsequent anniversary through January 1, 2024, equal to the lowest of 2,309,023 shares of Common Stock, 4% of the number of the Company’s outstanding shares on the first day of each such fiscal year and an amount determined by the Company’s board of directors.
	Also in January 2014, the Company’s board of directors and stockholders approved, effective upon the closing of the Company’s initial public offering, a 2014 Employee Stock Purchase Plan (the “2014 ESPP”). Under the 2014 ESPP, on the offering commencement date of each plan period (the “Purchase Plan Period”), the Company will grant to each eligible employee who is then a participant in the 2014 ESPP an option to purchase shares of Common Stock. The employee may authorize up to a maximum of 10% of his or her base pay to be deducted by the Company during the Purchase Plan Period. Each employee who continues to be a participant in the 2014 ESPP on the last business day of the Purchase Plan Period is deemed to have exercised the option, to the extent of accumulated payroll deductions within the 2014 ESPP ownership limits.
	Under the terms of the 2014 ESPP, the option exercise price shall be determined by the Company’s board of directors for each Purchase Plan Period and the option exercise price will be at least 85% of the applicable closing price of the Common Stock. The option exercise price will be 85% of the lower of the Company’s closing stock price on the first and last business day of each Purchase Plan Period. The Company’s first Purchase Plan Period commenced on September 2, 2014. Based upon 85% of the lower of the closing price at the beginning of the current offering period of $9.83 and the closing price on December 31, 2014 of $10.00, approximately 9,000 shares could be purchased based upon employee withholdings as of December 31, 2014.
	Upon the exercise of stock options, vesting of other awards and purchase of shares through the Company’s 2014 ESPP under the 2014 Plan, the Company issues new shares of common stock to the Company’s employees. All awards that are canceled prior to vesting or expire unexercised are returned to the approved pool of reserved shares under the 2014 Plan and made available for future grants. As of December 31, 2014, common stock remaining available for future issuance under the Company’s stock incentive plans totaled 4,200,717 shares and under the 2014 ESPP was 346,353 shares.
	As of December 31, 2011, substantially all of the Company’s employee stock option grants outstanding had exercise prices ranging from $10.86 to $36.66 per share. On March 31, 2012, the Board of Directors approved the repricing of stock options to purchase approximately 201,000 shares of the Company’s common stock at an exercise price of $4.20 per share. The revaluation of this modification of the exercise price of employee stock options did not result in additional stock compensation expense.
	The Company recorded the following stock-based compensation expense:
			Years Ended December 31,
			2012				2013				2014
	Research and development		$	511,860			$	524,495			$	1,604,215
	General and administrative			531,129				528,668				1,409,068
	Total stock-based compensation expense		$	1,042,989			$	1,053,163			$	3,013,283
	Allocations to research and development and general and administrative expense are based upon the department to which the associated employee reported. No related tax benefits of the stock-based compensation expense have been recognized. Stock-based payments issued to nonemployees are recorded at their fair values, and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period.
	Valuation Assumptions for Stock Option Plans
	The employee stock-based compensation expense recognized was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The weighted average assumptions used were as follows:
			2012				2013				2014
	Risk-free interest rate			1.2	%			2.12	%			2.26	%
	Expected dividend yield			0	%			0	%			0	%
	Expected option term (in years)			7				7				7
	Expected volatility			94	%			94	%			96	%
	The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant. The dividend yield percentage is zero because the Company neither currently pays dividends nor intends to do so during the expected option term. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore the Company estimates the expected term by using the simplified method allowed by the SEC. Expected stock price volatility is based on an average of several peer public companies. For purposes of identifying peer companies, the Company considered characteristics such as industry, length of trading history, similar vesting terms and in the-money option status. Upon the adoption of ASC 718, the Company was also required to estimate the level of forfeitures expected to occur and record compensation expense only for those awards that ultimately expect to vest. The Company performed a historical analysis of option awards that were forfeited prior to vesting and recorded total stock option expense that reflected this estimated forfeiture rate.
	The following table summarizes the Company’s stock option activity:
			Number of				Weighted				Weighted				Aggregate
			Shares				Average Exercise				Average				Intrinsic
							Price				Contractual				Value
											Term
											(in years)
	Outstanding as of December 31, 2013			1,957,069			$	5.48
	Granted			967,903			$	6.7
	Exercised			(3,050	)		$	4.2
	Cancelled			(74,825	)		$	4.94
	Outstanding as of December 31, 2014			2,847,097			$	5.89				8.65			$	11,796,921
	Exercisable as of December 31, 2014			897,294			$	5.04				7.54			$	4,509,931
	Vested and expected to vest as of December 31, 2014			2,716,363			$	5.86				8.62			$	11,255,225
	The aggregate intrinsic value of stock options in the table above represents the difference between the $10.00 closing price of the Company’s common stock as of December 31, 2014 and the exercise price of outstanding, exercisable, and vested and expected to vest in-the-money stock options.
	Included in amounts in the table above, the Company granted performance-based options to five executives to purchase a total of 160,500 shares of the Company’s common stock at an exercise price of $6.09 per share in July 2014. These options vest based on the successful completion of various performance requirements of each of the five executives at various times through December 31, 2018.
	The following table summarizes information about the Company’s stock options as of December 31, 2014:
	Exercise Price or Range of Exercise Price				Options Outstanding				Weighted Average				Options Exercisable
									Contractual Life
									(Years)
		$4.20				553,434				6.64				521,718
		$5.82				1,219,689				8.85				333,785
	$5.98	to	$6.62			869,525				9.5				—
	$7.32	to	$11.09			203,172				9.1				40,514
	$35.30	to	$36.66			1,271				6.7				1,271
	$135.78	to	$4,615.92			6				0.83				6
						2,847,097				8.65				897,294
	As of December 31, 2014, the Company had a total of $8,944,203 in unrecognized compensation expense from nonvested stock option awards, of which $3,069,553 is expected to be recognized in 2015, $2,898,537 in 2016, $2,427,924 in 2017, and $548,189 in 2018.

Note_13_Revenue_and_Concentrat

Note 13 - Revenue and Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	13. Revenue and Concentration of Credit Risk
	In September 2006, the Company entered into a multi-year research contract with NIH and NIAID to design, develop and clinically test an autologous HIV immunotherapy capable of eliciting therapeutic immune responses. The Company is using funds from this contract to develop AGS-004. Under this contract, as amended, the NIH and NIAID have committed to fund up to a total of $39.8 million, including reimbursement of direct expenses and allocated overhead and general and administrative expenses of up to $38.4 million and payment of other specified amounts totaling up to $1.4 million upon the Company’s achievement of specified development milestones. Since September 2010, the Company has received reimbursement of its allocated overhead and general and administrative expenses at provisional indirect cost rates equal to negotiated provisional indirect cost rates agreed to with the NIH and NIAID in September 2010. These provisional indirect cost rates are subject to adjustment based on the Company’s actual costs pursuant to the agreement with the NIH and NIAID. This commitment originally extended until May 2013. The Company agreed to an additional modification of the Company’s contract with the NIH and the NIAID under which the NIH and the NIAID agreed to increase their funding commitment to the Company by an additional $5.4 million in connection with the extension of the contract from May 2013 to September 2015. Additionally, a contract modification for a $0.5 million increase was agreed to by the NIH on September 18, 2014 to cover a portion of the manufacturing costs of the planned phase 2 clinical trial of AGS-004 for long-term viral control in pediatric patients. The NIH’s commitment under the contract extends to July 2016. The Company has agreed to a statement of work under the contract, and is obligated to furnish all the services, qualified personnel, material, equipment, and facilities, not otherwise provided by the U.S. government, needed to perform the statement of work.
	For the years ended December 31, 2012, 2013 and 2014, the Company recorded revenue under this agreement of $7,032,760, $4,421,689 and $1,797,054, respectively. The Company has recorded total revenue of $36.8 million through December 31, 2014 under the NIH agreement. As of December 31, 2014, there was up to $3.0 million of potential revenue remaining to be earned under the agreement with the NIH. As of December 31, 2013 and 2014, the Company recorded a receivable from the NIH and NIAID of $424,501 and $129,019, respectively, and a payable to subcontractors of $27,925 and $8,493, respectively.
	The Company’s grant revenue is earned under this contract with NIH and NIAID. The concentration of credit risk is equal to the outstanding accounts receivable and unbilled balances and such risk is subject to the credit worthiness of the NIH and NIAID. There have been no credit losses under this arrangement.

Note_14_License_Agreement

Note 14 - License Agreement	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	14. License Agreement
	In July 2011, the Company entered into an agreement with Celldex Therapeutics, Inc. (“Celldex”), pursuant to which Celldex granted the Company a nonexclusive license to specified patents and patent applications regarding actions necessary or helpful for processing dendritic cells. Upon the execution of the agreement, the Company paid Celldex $50,000 of a $100,000 up front license fee. The Company paid the balance of this fee on January 31, 2012. Under this agreement, the Company is required to pay:
		•	a $75,000 annual license fee;
		•	a specified milestone payment based on the achievement of a specified regulatory milestone; and
		•	a specified dollar amount per dose of AGS-003 the Company sells.
	The agreement will terminate on a country-by-country basis upon the expiration of the last to expire of the patent rights licensed under the agreement in a country. The latest date of expiration of the licensed Celldex patents is 2016.

Note_15_Collaboration_Agreemen

Note 15 - Collaboration Agreements	12 Months Ended
	Dec. 31, 2014
Contractors [Abstract]
Long-term Contracts or Programs Disclosure [Text Block]	15. Collaboration Agreements
	Pharmstandard License Agreement
	In August 2013, Pharmstandard, purchased shares of the Company’s series E preferred stock. Concurrently with such purchase, the Company entered into an exclusive royalty-bearing license agreement with Pharmstandard. Under this license agreement, the Company granted Pharmstandard and its affiliates a license, with the right to sublicense, to develop, manufacture and commercialize AGS-003 and other products for the treatment of human diseases, which are developed by Pharmstandard using the Company’s personalized immunotherapy platform, in the Russian Federation, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan, which the Company refers to as the Pharmstandard Territory. The Company also provided Pharmstandard with a right of first negotiation for development and commercialization rights in the Pharmstandard Territory to specified additional products the Company may develop.
	Under the terms of the license agreement, Pharmstandard licensed the Company rights to clinical data generated by Pharmstandard under the agreement and granted the Company an option to obtain an exclusive license outside of the Pharmstandard Territory to develop and commercialize improvements to the Company’s Arcelis technology generated by Pharmstandard under the agreement, a non-exclusive worldwide royalty-free license to Pharmstandard improvements to manufacture products using the Company’s Arcelis technology and a license to specified follow-on licensed products generated by Pharmstandard outside of the Pharmstandard Territory, each on terms to be negotiated upon the Company’s request for a license. In addition, Pharmstandard agreed to pay the Company pass-through royalties on net sales of all licensed products in the low single digits until it has generated a specified amount of aggregate net sales. Once the net sales threshold is achieved, Pharmstandard will pay the Company royalties on net sales of specified licensed products, including AGS-003, in the low double digits below 20%. These royalty obligations last until the later of the expiration of specified licensed patent rights in a country or the twelfth anniversary of the first commercial sale in such country on a country by country basis and no further royalties on specified other licensed products. After the net sales threshold is achieved, Pharmstandard has the right to offset a portion of the royalties Pharmstandard pays to third parties for licenses to necessary third party intellectual property against the royalties that Pharmstandard pays to the Company.
	The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid-up perpetual exclusive licenses. Either party may terminate the agreement for the other party’s uncured material breach or if specified conditions occur relating to the other party’s insolvency or bankruptcy and the Company may terminate the agreement if Pharmstandard challenges or assists a third party in challenging specified patent rights of ours. If Pharmstandard terminates the agreement upon the Company’s material breach or bankruptcy, Pharmstandard is entitled to terminate the Company’s licenses to improvements generated by Pharmstandard, upon which the Company may come to rely for the development and commercialization of AGS-003 and other licensed products outside of the Pharmstandard Territory, and to retain its licenses from the Company and to pay the Company substantially reduced royalty payments following such termination.
	In November 2013, the Company entered into an agreement with Pharmstandard under which Pharmstandard purchased additional shares of the Company’s series E preferred stock. Under this agreement, the Company agreed to enter into a manufacturing rights agreement for the European market with Pharmstandard and that the manufacturing rights agreement would provide for the issuance of warrants to Pharmstandard to purchase 499,788 shares of the Company’s common stock at an exercise price of $5.82 per share. The Company has not entered into this manufacturing rights agreement or issued the warrants. On February 12, 2014, all outstanding shares of our preferred stock converted into shares of our common stock upon the closing of our initial public offering.
	Green Cross License Agreement
	In July 2013, the Company entered into an exclusive royalty-bearing license agreement with Green Cross. Under this agreement the Company granted Green Cross a license to develop, manufacture and commercialize AGS-003 for mRCC in South Korea. The Company also provided Green Cross with a right of first negotiation for development and commercialization rights in South Korea to specified additional products the Company may develop.
	Under the terms of the license, Green Cross has agreed to pay the Company $500,000 upon the initial submission of an application for regulatory approval of a licensed product in South Korea, $500,000 upon the initial regulatory approval of a licensed product in South Korea and royalties ranging from the mid-single digits to low double digits below 20% on net sales until the fifteenth anniversary of the first commercial sale in South Korea. In addition, Green Cross has granted the Company an exclusive royalty free license to develop and commercialize all Green Cross improvements to the Company’s licensed intellectual property in the rest of the world, excluding South Korea, except that, as to such improvements for which Green Cross makes a significant financial investment and that generate significant commercial benefit in the rest of the world, the Company is required to negotiate in good faith a reasonable royalty that the Company will be obligated to pay to Green Cross for such license. Under the terms of the agreement, the Company is required to continue to develop and to use commercially reasonable efforts to obtain regulatory approval for AGS-003 in the United States.
	The agreement will terminate upon expiration of the royalty term, which is 15 years from the first commercial sale, upon which all licenses will become fully paid up perpetual non-exclusive licenses. Either party may terminate the agreement for the other party’s uncured material breach or if specified conditions occur relating to the other party’s insolvency or bankruptcy and the Company may terminate the agreement if Green Cross challenges or assists a third party in challenging specified patent rights of ours. If Green Cross terminates the agreement upon the Company’s material breach or bankruptcy, Green Cross is entitled to terminate the Company’s licenses to improvements and retain its licenses from the Company and to pay the Company substantially reduced milestone and royalty payments following such termination.
	Medinet License Agreement
	In December 2013, the Company entered into a license agreement with Medinet. Under this agreement, the Company granted Medinet an exclusive, royalty-free license to manufacture in Japan AGS-003 and other products using the Company’s Arcelis technology solely for the purpose of the development and commercialization of AGS-003 and these other products for the treatment of mRCC. The Company refers to this license as the manufacturing license. In addition, under this agreement, the Company granted Medinet an option to acquire a nonexclusive, royalty-bearing license under the Company’s Arcelis technology to sell in Japan AGS-003 and other products for the treatment of mRCC. The Company refers to the option as the sale option and the license as the sale license.
	Under the manufacturing license, if Medinet does not exercise the sale option, Medinet may only manufacture AGS-003 and these other products for the Company or its designee. If Medinet does not exercise the sale option, the Company and Medinet have agreed to negotiate in good faith a supply agreement under which Medinet would supply the Company or its designee with AGS-003 and these other products for development and sale for the treatment of mRCC in Japan. If Medinet exercises the sale option, it may only manufacture AGS-003 and these other products for itself, its related parties and its sublicensees. During the term of the manufacturing license, the Company may not manufacture AGS-003 or these other products for the Company or any designee for development or sale for the treatment of mRCC in Japan.
	Medinet may exercise the option at any time until the earlier of December 31, 2015 and the date 30 days after the Company has provided Medinet with an interim report on the Company’s phase 3 clinical trial of AGS-003 following such time as 50% of the required events in the trial have occurred.
	In consideration for the manufacturing license, Medinet paid the Company $1.0 million. Medinet also loaned the Company $9.0 million in connection with the Company entering into the agreement. The Company has agreed to use these funds in the development and manufacturing of AGS-003 and the other products. Medinet also agreed to pay the Company milestone payments of up to a total of $9.0 million upon the achievement of developmental and regulatory milestones and $5.0 million upon the achievement of a sales milestone related to AGS-003 and these products. If Medinet exercises the sale option, it will pay the Company $1.0 million, as well as royalties on net sales at a rate to be negotiated until the later of the expiration of the licensed patent rights in Japan and the twelfth anniversary of the first commercial sale in Japan. If the Company and Medinet cannot agree on the royalty rate, the Company and Medinet have agreed to submit the matter to arbitration.
	In December 2013, in connection with the manufacturing license agreement with Medinet, the Company borrowed the $9.0 million pursuant to an unsecured promissory note that bears interest at a rate of 3.0% per annum. The principal and interest under the note are due and payable on December 31, 2018. Under the terms of the note and the manufacturing license agreement, any milestone payments related to the developmental and regulatory milestones that become due will be applied first to the repayment of the loan. The Company has the right to prepay the loan at any time. If the Company has not repaid the loan by December 31, 2018, then the Company has agreed to grant to Medinet a non-exclusive, royalty-bearing license to make and sell Arcelis products in Japan for the treatment of cancer. In such event, the amounts owing under the loan as of December 18, 2018 may constitute pre-paid royalties under the license or would be due and payable. Royalties under this license would be paid until the expiration of the licensed patent rights in Japan at a rate to be negotiated. If the Company and Medinet cannot agree on the royalty rate, Company and Medinet have agreed to submit the matter to arbitration. The Company recorded the $1.0 million payment from Medinet as a deferred liability. In addition, because the $9.0 million promissory note was issued at a below market interest rate, the Company allocated the proceeds of the loan between the manufacturing license agreement and the debt at the time of issuance. Accordingly, as of December 31, 2013, the Company recorded $6.9 million to notes payable, based upon an effective interest rate of 8.0%, and $2.1 million as a deferred liability. As of December 31, 2014, the Company recorded $7.6 million to notes payable, including $0.7 million accrued interest recorded during the year ended December 31, 2014. The total deferred liability was $3.1 million as of December 31, 2014 including the $1.0 million received by the Company for the manufacturing license.
	The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid up, perpetual non-exclusive licenses. Either party may terminate the agreement for the other party’s uncured material breach or if specified conditions occur relating to the other party’s insolvency or bankruptcy, and the Company may terminate the agreement if Medinet challenges or assists a third party in challenging specified patent rights of the Company. If Medinet terminates the agreement upon the Company’s material breach or bankruptcy, Medinet is entitled to terminate the Company’s licenses to improvements and retain its royalty-bearing licenses from the Company.

Note_16_Facility_Lease_Obligat

Note 16 - Facility Lease Obligation	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	16. Facility Lease Obligation
	On August 18, 2014,  the Company entered into a Lease Agreement (the “Lease Agreement”) with TKC LXXII, LLC, a North Carolina limited liability company (“TKC”).
	Under the Lease Agreement, the Company agreed to lease certain land and an approximately 120,000 square-foot building to be constructed on approximately 11 acres in Durham County, North Carolina. This facility will house the Company’s corporate headquarters and primary manufacturing facility.  The Lease Agreement is intended to replace the Company’s existing lease, located at 4233 Technology Drive, Durham North Carolina, which currently expires in November 2016. The shell of the new facility will be constructed on a build-to-suit basis by TKC, at its expense, in accordance with agreed upon specifications and plans as set forth in the Lease Agreement.
	The term of the Lease Agreement will be 10 years from the commencement date for the initial term, currently estimated to be May 1, 2015, with the Company having the option to extend the Lease Agreement by six five-year renewal terms. Initial rent will be approximately $46,917 per month, subject to certain fixed increases over the course of the term as set forth in the Lease Agreement and to adjustment based on the Company’s use of certain amounts allocated for upfitting the interior of the facility.
	The Lease Agreement required us to provide the landlord with a letter of credit. We have provided the bank that issued the letter of credit on our behalf a security deposit of $1.325 million to guarantee the letter of credit. The deposit is recorded as a long-term investment as of December 31, 2014 on our consolidated balance sheet.
	Under the Lease Agreement, the Company had an option to purchase the property for an amount estimated at $7.6 million. On February 16, 2015, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with TKC which represented the Company’s exercise of its purchase option under the Lease Agreement. The purchase price to be paid by the Company is $7.6 million plus the amount of any additional costs incurred by TKC as a result of changes requested by the Company and the amount of any improvement allowances advanced to the Company by TKC prior to the closing. The Purchase Agreement is expected to close in the second half of 2015. Upon the closing, the Lease Agreement will terminate.
	Under the Lease Agreement, the Company is deemed to be the owner of this facility during its construction period under build-to-suit lease accounting. The Company therefore recorded an asset related to the facility lease obligation included in property and equipment of $3.4 million during the year ended December 31, 2014. The facility lease obligation on the Company’s consolidated balance sheet is $3.4 million as of December 31, 2014.
	If the Purchase Agreement is not executed, future minimum payments due under the Lease Agreement are as follows as of December 31, 2014:
	Year ending December 31:
	2015	$	375,333
	2016		571,445
	2017		584,303
	2018		597,449
	2019		610,892
	Thereafter		3,496,201
	Total future minimum lease payments	$	6,235,623

Note_17_Manufacturing_Research

Note 17 - Manufacturing Research and Development Obligation	12 Months Ended
	Dec. 31, 2014
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure [Text Block]	17. Manufacturing Research and Development Obligation
	On October, 29, 2014, the Company entered into a development agreement (the “Invetech Development Agreement”) with Invetech Pty Ltd (“Invetech”). The Invetech Development Agreement supersedes and replaces the development agreement entered into by the parties as of July 20, 2005. Under the Invetech Development Agreement, Invetech will continue to develop and provide prototypes of the automated production system to be used for the manufacture of the Company’s Arcelis-based products, or the Production Systems. Development services will be performed on a proposal by proposal basis.
	Invetech will defer 30% of its fees, but such deferral will not exceed $5,000,000.  Deferred fees (plus interest of 7% per annum) would become payable either, at the Company’s option, in lump sum within 90 days of the “Sunset Date Trigger Event” or pursuant to an installment plan (either in four installments payable within the first year or eight installments payable within the first two years after the “Sunset Date Trigger Event”). The “Sunset Date Trigger Event” is June 30, 2016 if our current Phase 3 ADAPT clinical trial (the “Trial”) is closed early indicating positive efficacy; otherwise, December 31, 2016. Invetech is entitled to a 10% bonus payment if the Trial is closed early indicating positive efficacy and Invetech has timely completed all activities up to the time of such early closure.
	As of December 31, 2014, the Company has recorded a long-term portion of this manufacturing research and development obligation on its consolidated balance sheet totaling $3.5 million representing $2.5 million in deferred fees, $0.9 million in estimated bonus payments and $34,330 in accrued interest.
	The Invetech Development Agreement requires the parties to discuss in good faith Invetech’s supply of Production Systems for use in manufacturing commercial product. The Company has an obligation to purchase $25.0 million worth of Production Systems, components, subsystems and spare parts for commercial use. Once that obligation has been satisfied, the Company has the right to have a third party supply Production Systems for use in manufacturing commercial product provided that Invetech has a right of first refusal with respect to any offer by a third party and the Company may not accept an offer from a third party unless that offer is at a price that is less than that offered by Invetech and otherwise under substantially the same or better terms. The Company will own all intellectual property arising from the development services (with the exception of existing Invetech intellectual property incorporated therein-under which the Company will have a license).  The Invetech Development Agreement will continue until the completion of the development of the Production Systems. The Invetech Development Agreement can be terminated early by either party because of a technical failure or by the Company without cause.

Note_18_Commitments

Note 18 - Commitments	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Commitments Disclosure [Text Block]	18. Commitments
	The Company rents laboratory and office space and equipment under operating leases that expire in various years through 2017. Future minimum lease payments under noncancelable operating leases as of December 31, 2014 are as follows:
	2015	$	394,089
	2016		435,359
	2017		79,688
	Total minimum lease payments	$	909,136
	Rent expense related to operating leases for the years ended December 31, 2012, 2013 and 2014 was $361,356, $348,191 and $447,918, respectively.
	The Company has entered into various licensing agreements with universities and other research institutions under which the Company receives substantially all rights of the inventors or co-assignee to produce and market technology protected by certain patents and patent applications. The Company also entered into various assignment agreements with a scientist under which the Company receives exclusive rights to produce and market technology protected by certain patents and patent applications.
	The Company is generally required to make royalty payments ranging from 1% to 4 % of future sales of products employing the technology or falling under claims of a patent. If future sales require the use of technology licensed from multiple different sources, the total royalty rates could be higher. As royalty payments are directly related to future sales volume, future commitments cannot be determined. No accrual for future payments under these agreements has been recorded, as the Company cannot estimate if, when or in what amount payments may become due.
	In connection with the Loan and Security Agreement with two lending institutions in April 2007, the Company is required to pay a success fee of $200,000 upon consummation of a liquidity event, including an initial public offering. This was paid in March 2014 upon the successful completion of the Company’s initial public offering.

Note_19_Employee_Benefit_Plan

Note 19 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	19. Employee Benefit Plan
	The Company provides a retirement plan qualified under section 401(k) of the Internal Revenue Code of 1986, as amended (“IRC”). Participants may elect to contribute a portion of their annual compensation to the plan, after complying with certain limitations set by the IRC. All employees are eligible to participate in the plan after attaining the age of 21. The Company matched 25% of the first 6% contributed by eligible participants in the plan during the years ended December 31, 2012, 2013 and 2014, or $71,571, $101,700 and $121,399, respectively.

Note_20_Net_Loss_Per_Share

Note 20 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	20. Net Loss Per Share
	Basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. The Company’s potentially dilutive shares, which include redeemable convertible preferred stock, common stock options and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.
	The following table presents the computation of basic and diluted net loss per share of common stock:
		Year Ended December 31,
		2012			2013			2014
	Net loss	$	(10,471,330	)	$	(23,921,563	)	$	(53,305,938	)
	Accretion of redeemable convertible preferred stock		(351,371	)		(884,647	)		(863,226	)
	Reverse prior accretion on redeemable preferred stock due to reduction in liquidation value of Series A, B, and C		—			5,657,638			—
	Preferred stock dividend due to exchanges of preferred shares		—			(14,726,088	)		—
	Net loss attributable to common stockholders	$	(10,822,701	)	$	(33,874,660	)	$	(54,169,164	)
	Weighted average common shares outstanding, basic and diluted		198,306			229,865			17,367,665
	Net loss per share attributable to common stockholders, basic and diluted	$	(54.58	)	$	(147.37	)	$	(3.12	)
	The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:
		Year Ended December 31,
		2012			2013			2014
	Redeemable convertible preferred stock		2,167,143			6,322,747			—
	Stock options outstanding		366,389			767,510			2,847,097
	Warrants outstanding		316,184			424,961			82,781

Note_21_Selected_Quarterly_Dat

Note 21 - Selected Quarterly Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	21. Selected Quarterly Data (unaudited)
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2014			2014			2014			2014
	Revenue	$	798,788		$	473,163		$	398,615		$	303,453
	Operating expenses:
	Research and development		8,472,195			10,569,134			12,998,409			13,459,178
	General and administrative		1,933,476			1,865,822			2,320,036			2,480,025
	Operating loss		(9,606,883	)		(11,961,793	)		(14,919,830	)		(15,635,750	)
	Other income (expense), net		(394,097	)		(21,738	)		(181,187	)		(584,660	)
	Net loss		(10,000,980	)		(11,983,531	)		(15,101,017	)		(16,220,410	)
	Accretion of redeemable convertible preferred stock		(863,226	)		—			—			—
	Less: Preferred stock dividend due to exchanges of preferred shares		-			-			-			-
	Net loss attributable to common stockholders	$	(10,864,206	)	$	(11,983,531	)	$	(15,101,017	)	$	(16,220,410	)
	Net loss attributable to common stockholders per share, basic and diluted	$	(1.05	)	$	(0.61	)	$	(0.77	)	$	(0.83	)
	Weighted average shares outstanding, basic and diluted		10,376,561			19,655,187			19,655,561			19,656,209
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Revenue	$	1,461,687		$	1,263,008		$	981,247		$	715,747
	Operating expenses:
	Research and development		5,189,461			6,102,320			5,630,219			7,069,151
	General and administrative		1,078,357			939,725			1,024,167			1,620,068
	Operating loss		(4,806,131	)		(5,779,037	)		(5,673,139	)		(7,973,472	)
	Other income (expense), net		356,929			196			541			(47,450	)
	Net loss		(4,449,202	)		(5,778,841	)		(5,672,598	)		(8,020,922	)
	Accretion of redeemable convertible preferred stock		(64,940	)		(10,446	)		5,325,406			(477,029	)
	Less: Preferred stock dividend due to exchanges of preferred shares		—			—			(14,726,088	)		—
	Net loss attributable to common stockholders	$	(4,514,142	)	$	(5,789,287	)	$	(15,073,280	)	$	(8,497,951	)
	Net loss attributable to common stockholders per share, basic and diluted	$	(19.91	)	$	(25.53	)	$	(65.23	)	$	(36.19	)
	Weighted average shares outstanding, basic and diluted		226,757			226,757			231,084			234,789

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Schedule II—Valuation and Qualifying Accounts
	Deferred Tax Asset Valuation Allowance
	Information presented below is in thousands:
					Additions
			Balance at		Charged to		Charged to		Increases		Balance at
			Beginning		Expenses		Other				End of Year
			of Year		(a)		Accounts
	Year Ended December 31, 2014		$	47,945	$	20,252	$	—	$	—	$	68,197
	Year Ended December 31, 2013		$	39,134	$	8,811	$	—	$	—	$	47,945
	Year Ended December 31, 2012		$	36,515	$	2,619	$	—	$	—	$	39,134
	(a)	– Impact of providing full valuation allowance against all deferred tax assets since the Company could not assert that it was more likely than not that these deferred tax assets would be realized.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Stockholders' Equity, Policy [Policy Text Block]	Initial Public Offering
	In February 2014, the Company issued and sold 6,228,725 shares of its common stock, including 603,725 shares of common stock sold pursuant to the underwriters’ exercise of their option to purchase additional shares, in the Company’s initial public offering, at a public offering price of $8.00 per share, for aggregate gross proceeds of $49.8 million. The net offering proceeds to the Company, after deducting underwriting discounts and commissions of approximately $3.5 million and offering expenses of approximately $2.9 million, were approximately $43.4 million. Upon the closing of the initial public offering, all of the then-outstanding shares of the Company’s redeemable convertible preferred stock automatically converted into 13,188,251 shares of common stock.
	In connection with the initial public offering, the Company paid a former lender a $200,000 under a Loan and Security Agreement entered into with two lending institutions in April 2007. The Loan and Security Agreement terminated in April 2010, and the Company repaid all amounts owing under the Loan and Security Agreement. In connection with the Loan and Security Agreement, the Company was required to pay a success fee of $200,000 upon consummation of a liquidity event, including an initial public offering. Accordingly, the Company paid this fee in March 2014. The Company recorded this fee in Other expense on the Condensed Consolidated Statements of Operations during the year ended December 31, 2014.
	There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company expects to continue to incur losses and require additional financial resources to advance its products to either commercial stage or liquidity events.
	Capitalization
	In connection with the Company’s initial public offering in February 2014, the Company effected a one–for-six reverse split of its common stock. All references to shares of common stock outstanding, average number of shares outstanding and per share amounts in these consolidated financial statements and notes to consolidated financial statements have been restated to reflect the reverse split on a retroactive basis.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts and results of operations of the Company and DC Bio, formerly Merix Canada Corp., an unlimited liability corporation incorporated in the Province of Nova Scotia. Prior to October 26, 2012, the Company consolidated DC Bio under ASC 810-10-50, Consolidation of Variable Interest Entities (“VIE”), as DC Bio met the requirements of a VIE. As of December 31, 2012, the Company owned 100% of DC Bio through the repurchase of the noncontrolling interests of DC Bio. All intercompany balances and transactions have been eliminated in consolidation.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share
	Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less as of the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States of America or Canada. The Company maintains cash in accounts which are in excess of federally insured limits. As of December 31, 2013 and December 31, 2014, $33,047,970 and $36,973,590, respectively, in cash and cash equivalents was uninsured.
Marketable Securities, Policy [Policy Text Block]	Short-Term Investments
	All investments with original maturities less than one year from the balance sheet date are considered short-term investments. All short-term investments are classified as available-for-sale and therefore carried at fair value. Generally, the fair value of short-term investments approximates amortized cost. The Company primarily invests in high-quality marketable debt securities issued by high quality financial and industrial companies.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments. Total cash and cash equivalent balances have exceeded insured balances by the Federal Depository Insurance Company (“FDIC”).
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Property and equipment held under capital leases and leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. Repairs and maintenance costs are expensed as incurred.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
	The Company periodically assesses the impairment of long lived assets in accordance with ASC Topic 360, Property Plant and Equipment. When indicators of impairment are present, the Company evaluates the carrying value of these assets in relation to the operating performance of the business and future undiscounted cash flows expected to result from the use of these assets. No such impairments have been recognized during the years ended December 31, 2012, 2013 or 2014.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	The Company recognizes revenue in accordance with the FASB Accounting Standards Codification 605, Revenue Recognition, or ASC 605. The Company recognizes revenue when the following criteria are met: persuasive evidence of an arrangement exists, services have been rendered, the price is fixed or determinable, and collectability is reasonably assured.
	The Company has entered into license agreements with collaborators. The terms of these agreements have included nonrefundable signing and licensing fees, as well as milestone payments and royalties on any future product sales developed by the collaborators under such licenses. The Company assesses these multiple elements in accordance with ASC 605, to determine whether particular components of the arrangement represent separate units of accounting.
	These collaboration agreements will be accounted for in accordance with Accounting Standards Update, or ASU, No. 2009-13, Topic 605 – Multiple-Deliverable Revenue Arrangements, or ASU 2009-13. This guidance requires the application of the “relative selling price” method when allocating revenue in a multiple deliverable arrangement. The selling price for each deliverable shall be determined using vendor specific objective evidence of selling price, if it exists; otherwise, third-party evidence of selling price shall be used. If neither exists for a deliverable, the vendor shall use its best estimate of the selling price for that deliverable. The Company recognizes upfront license payments as revenue upon delivery of the license only if the license has standalone value and the fair value of the undelivered performance obligations can be determined. If the fair value of the undelivered performance obligations can be determined, such obligations are accounted for separately as the obligations are fulfilled. If the license is considered to either not have stand-alone value or have stand-alone value but the fair value of any of the undelivered performance obligations cannot be determined, the arrangement is accounted for as a single unit of accounting and the license payments and payments for performance obligations are recognized as revenue over the estimated period of when the performance obligations are performed.
	When the Company determines that an arrangement should be accounted for as a single unit of accounting, the Company must determine the period over which the performance obligations will be performed and revenue will be recognized, to the extent this is determinable. If the timing and the level of effort to complete performance obligations under the arrangement is not estimable, then the Company recognizes revenue under the arrangement on a straight-line basis over the period that the Company expects to complete such performance obligations.
	The Company’s license agreements with Pharmstandard International S.A. (“Pharmstandard”), Medinet Co., Ltd. (“Medinet”) and Green Cross Corp. (“Green Cross”) contain, and other agreements it enters into may also contain, milestone payments. Revenues from milestones, if they are non-refundable and considered substantive, are recognized upon successful accomplishment of the milestones. If not considered substantive, milestones are initially deferred and recognized over the remaining performance obligation.
	The Company’s current license agreements with Pharmstandard, Medinet and Green Cross and any future license agreements the Company may enter into may provide for royalty payments. Royalty revenue is recognized upon the sale of the related products, provided there are no remaining performance obligations under the arrangement. To date, the Company has not received any royalty payments.
	The Company conducted AGS-004 a phase 2b clinical trial of AGS-004 that was funded entirely by the National Institutes of Health (“NIH”) and National Institute of Allergy and Infectious Diseases (“NIAID”). Under the NIH and NIAID agreement, as amended, the Company is entitled to receive reimbursement of its direct expenses and allocated overhead and general and administrative expenses of up to $38.4 million and payment of other specified amounts totaling up to $1.4 million upon its achievement of specified development milestones. These reimbursable expenses and allocated overhead are directly related to the development of novel HIV immunotherapy candidates and are recognized as revenue based on the reimbursable expenses that have accrued in accordance with the contractual terms in the arrangement. The Company recognizes revenues from the achievement of milestones under the NIH contract upon the accomplishment of any such milestone.
Income Tax, Policy [Policy Text Block]	Income Taxes
	The Company provides for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
Segment Reporting, Policy [Policy Text Block]	Segment and Geographic Information
	Operating segments are defined as components of an enterprise engaging in business activities from which it may earn revenues and incur expenses, for which discrete financial information is available and whose operating results are regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and all of the Company operations are in North America.
Research and Development Expense, Policy [Policy Text Block]	Research and Development
	Research and development costs include all direct costs related to the development of the Company’s technology, including salaries and related benefits of research and development (“R&D”) personnel, depreciation of laboratory equipment, fees paid to consultants and contract research organizations, stock-based compensation for R&D personnel, sponsored research payments and license fees. R&D costs are expensed as incurred.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	Redeemable Convertible Preferred Stock
	The carrying value of redeemable convertible preferred stock is increased by periodic accretions so that the carrying amount will equal the redemption amount as of the redemption date. These increases were recorded through charges against additional paid-in capital, to the extent it was available, or the accumulated deficit.
Warrant Liability Policy [Policy Text Block]	Warrant Liability
	Warrants to purchase the Company’s convertible preferred stock were classified as liabilities and recorded at their estimated fair value. In each reporting period, any change in fair value of the freestanding warrants are recorded as expense in the case of an increase in fair value and income in the case of a decrease in fair value.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Other Receivables
	The Company has recorded other receivables of $424,501 and $129,019 as of December 31, 2013 and 2014. These receivables are primarily related to amounts due under the NIH contract as of such dates. The Company assesses the recoverability of other receivables as of each balance sheet date.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	The Company estimates the grant date fair value of its share-based awards and amortizes this fair value to compensation expense over the requisite service period or vesting term (see Note 12).
Investment Tax Credits [Policy Text Block]	Investment Tax Credits
	Other income of $694,331, $0 and $140,556 was recognized during the years ended December 31, 2012, 2013 and 2014, respectively, for scientific research and experimental development (“SR&ED”) investment tax credits in Canada. Under Canadian and Ontario law, the Company’s Canadian subsidiary is entitled to SR&ED. Because these credits are subject to a claims review, the Company recognizes such credits when received.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss)
	ASC 220, Comprehensive Income, establishes standards for reporting and display of comprehensive income and its components in a full set of financial statements. The Company’s other comprehensive income (loss) is related to foreign currency translation adjustments and unrealized gain (loss) on short-term investments.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation
	Gains and losses from foreign currency transactions are reflected in income currently.
	The Company has identified the functional currency of its subsidiaries with foreign operations as the applicable local currency. The translation from the applicable local currency to United States dollars is performed using the exchange rate in effect as of the balance sheet date. Revenue and expense accounts are translated using the average exchange rate experienced during the period. Adjustments resulting from the translation of the Company’s subsidiaries’ financial statements from its functional currency to the United States dollar are not included in determining net loss, but are reported as accumulated other comprehensive gain (loss), a separate component of stockholders’ (deficit) equity.
Derivatives, Policy [Policy Text Block]	Derivatives
	The Company issued a put option to exchange certain shareholders’ stock in DC Bio for stock in the Company (see Note 5). Derivatives are recorded in the balance sheet at fair value as of each balance sheet date utilizing pricing models for nonexchange traded contracts (see Note 9). The Company does not use derivative financial instruments for speculative purposes. As of December 31, 2013 and 2014, there were no derivatives outstanding.
Interest Expense, Policy [Policy Text Block]	Interest Expense
	During the year ended December 31, 2014, interest expense primarily resulted from accrued interest on our note payable to Medinet, which was issued in December 2013, and interest from a venture loan and security agreement entered into in September 2014 with two financial institutions (see Note 8).
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued a new accounting standard update pertaining to disclosures for development stage entities. The new guidance eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The new standard is effective prospectively for annual reporting beginning after December 15, 2014, and interim periods within those annual periods, but early adoption is permitted. The Company adopted this new accounting standard during the three months ended June 30, 2014.
	In May 2014, the FASB issued a new accounting standard update pertaining to accounting for revenue from contracts with customers. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.
	In August 2014, the FASB issued a new standard update that specifies the responsibility that an entity’s management has to evaluate whether there is substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for interim and annual periods beginning after December 15, 2016, and is not expected to have an effect on the Company’s financial statements.
	In July 2013, the FASB issued a new accounting standard update on the financial statement presentation of unrecognized tax benefits. The new guidance provides that a liability related to an unrecognized tax benefit would be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. The new guidance became effective for the Company on January 1, 2014 and it was applied prospectively to unrecognized tax benefits that existed as of the effective date with retrospective application permitted. This updated standard did not have a material impact on the Company’s condensed consolidated financial statements.

Note_3_Fair_Value_of_Financial1

Note 3 - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]		Quoted Prices		Significant			Significant			Balance as of
		in Active		Other			Unobservable			December 31,
		Markets for		Observable			Inputs			2013
		Identical Assets		Inputs			(Level 3)
		(Level 1)		(Level 2)
	Assets
	Money-market funds	$	22,891,418	$	—		$	—		$	22,891,418
	Corporate debt securities – short-term		—		13,659,812			—			13,659,812
	Total assets at fair value	$	22,891,418	$	13,659,812		$	—		$	36,551,230
		Quoted Prices		Significant			Significant			Balance as of
		in Active		Other			Unobservable			December 31,
		Markets for		Observable			Inputs			2014
		Identical Assets		Inputs			(Level 3)
		(Level 1)		(Level 2)
	Assets
	Money-market funds	$	35,541,595	$	—		$	—		$	35,541,595
	Corporate debt securities – short-term		—		20,266,243			—			20,266,243
	Restricted cash – long-term		1,325,000								1,325,000
	Total assets at fair value	$	36,866,595	$	20,266,243		$	—		$	57,132,838
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]		Fair Value Measurements Using Significant Unobservable
		Inputs (Level 3)
		Beginning		Net Change in			Reduction			Ending
		Balance		Unrealized						Balance
				(Gains) Losses
	Warrant Liability	$	6,392,652	$	(355,352	)	$	(6,037,300	)	$	—
		$	6,392,652	$	(355,352	)	$	(6,037,300	)	$	—

Note_4_Property_and_Equipment_

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Note 4 - Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]		Useful Life		31-Dec-13			31-Dec-14
		(Years)
	Office furniture and equipment	7		$	528,732		$	458,380
	Computer equipment	3			712,609			788,563
	Computer software	3			540,809			629,948
	Laboratory equipment	7			5,264,952			5,345,786
	Leasehold improvements	5			2,643,023			2,646,891
	Asset related to facility lease obligation				—			3,380,223
	Construction of manufacturing facility in progress				76,010			500,093
					9,766,135			13,749,884
	Less: Accumulated depreciation and amortization				(8,164,032	)		(8,236,329	)
	Property and equipment, net			$	1,602,103		$	5,513,555
Depreciation and Amortization Expense [Member]
Note 4 - Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Year ended December 31, 2012	$	505,261
	Year ended December 31, 2013		611,421
	Year ended December 31, 2014		566,117

Note_6_Income_Taxes_Tables

Note 6 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		December 31,
		2013			2014
	U.S. federal and state net operating loss carryforwards	$	41,359,722		$	59,689,264
	Foreign net operating loss carryforwards		1,827,221			1,743,603
	Contribution carryforwards		3,055			4,245
	Research and development credits		4,061,844			5,253,055
	Investment tax credits		38,175			35,108
	Stock-based compensation		22,282			462,796
	Patents and other intangibles		2,967			611
	Other accruals		97,157			125,614
	Deferred revenue		—			372,040
	Property and equipment		532,316			510,466
	Total deferred tax assets		47,944,739			68,196,802
	Valuation allowance for deferred assets		(47,944,739	)		(68,196,802	)
	Net deferred tax assets	$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		December 31,						December 31,						December 31,
		2011						2012						2014
		Amount			Percent of			Amount			Percent of			Amount			Percent of
					Pretax						Pretax						Pretax
					Earnings						Earnings						Earnings
	U.S. federal tax statutory rate	$	(3,560,252	)		34	%	$	(8,133,331	)		34	%	$	(18,124,019	)		34	%
	State taxes (net of federal benefit)		(476,446	)		4.5	%		(789,412	)		3.3	%		(1,707,912	)		3.2	%
	U.S. federal research and development tax credits		—			0	%		(1,262,562	)		5.3	%		(1,701,727	)		3.2	%
	Nondeductible interest expense		(1,782,830	)		17	%		(132,546	)		0.6	%		—			0	%
	Other nondeductible expenses		(210,790	)		2	%		419,934			(1.8	%)		658,740			(1.1	%)
	Expiration of capital loss carryforward		3,246,049			(31.0	%)		—			(0.0	%)		—			0	%
	Increase in unrecognized tax benefits		—			0	%		378,769			(1.6	%)		510,516			(1.0	%)
	Change in effective state tax rate		—			0	%		1,349,062			(5.6	%)		1,685			(0.0	%)
	Expiration of NOL & contribution carryforwards		57,538			(0.5	%)		6,630			(0.0	%)		77,391			(0.1	%)
	Change in valuation reserves		2,618,552			(25.2	%)		8,811,127			(36.8	%)		20,252,063			(38.1	%)
	Deferred tax asset true-ups		108,179			(0.8	%)		(647,671	)		2.6	%		33,263			(0.1	%)
	Provision for income taxes	$	—			0	%	$	—			0	%	$	—			0	%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]		2012			2013			2014
	Beginning balance	$	1,272,800		$	1,265,700		$	1,644,500
	Gross increase for tax positions related to current periods		—			378,800			474,300
	Gross (decrease) increase for tax positions related to prior periods		(7,100	)		—			36,200
	Ending balance	$	1,265,700		$	1,644,500		$	2,155,000

Note_8_Notes_Payable_Tables

Note 8 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]		December 31,			December 31,
		2013			2014
	Notes payable under the venture loan and security agreement	$	—		$	12,500,000
	Less related debt discount		—			(373,756	)
	Notes payable under the venture loan and security agreement, net of debt discount		—			12,126,244
	Promissory note payable to Medinet including accrued interest		6,936,466			7,623,546
	Other notes payable		123,087			77,640
	Total notes payable		7,059,553			19,827,430
	Less current portion		(45,447	)		(30,885	)
	Long-term portion of notes payable	$	7,014,106		$	19,796,545

Note_10_Common_Stock_Redeemabl1

Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stock by Class [Table Text Block]		Series A Preferred						Series B Preferred						Series B-1						Series C Preferred						Series D Preferred						Series D-1 Preferred						Series E Preferred
														Preferred
		Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount
	Balance as of December 31, 2011		1,276,103		$	1,276,103			24,326,574		$	42,814,762			917,771		$	1,615,276			112,165,271		$	32,016,165			—		$	—			—		$	—			—		$	—
	Issuance of shares		—			—			—			—			—			—			—			—			2,549,897			4,793,806			3,713,333			7,842,733			—			—
	Conversion of bridge note		—			—			—			—			—			—			—			—			3,023,661			5,684,483			—			—			—			—
	Conversion of accrued services		—			—			—			—			—			—			—			—			7,142			25,200			3,602			15,485			—			—
	Pull through of existing preferred		—			—			(3,652,680	)		(6,428,717	)		—			—			(64,256,463	)		(18,571,283	)		2,557,039			4,807,233			3,716,935			7,835,133			—			—
	Stock issuance costs		—			—			—			—			—			—			—			—			—			(128,275	)		—			(80,659	)		—			—
	Shares converted to common		(124,050	)		(124,050	)		(2,182,576	)		(3,841,332	)		(917,771	)		(1,615,276	)		(8,605,955	)		(2,487,276	)		—			—			—			—			—			—
	Accretion		—			—			—			—			—			—			—			327,465			—			18,529			—			5,377			—			—
	Balance as of December 31, 2012		1,152,053			1,152,053			18,491,318			32,544,713			—			—			39,302,853			11,285,071			8,137,739			15,200,976			7,433,870			15,618,069			—			—
	Exchange of Series D-1		—			—			—			—			—			—			—			—			16,151,212			26,887,407			(7,433,870	)		(15,628,821	)		—			—
	Issuance of shares		—			—			—			—			—			—			—			—			6,373,782			11,446,143			—			—			36,856,922			47,409,867
	Exchange of Series D		—			—			—			—			—			—			—			—			(12,607,779	)		(24,945,326	)		—			—			19,154,336			24,945,326
	Pull through of existing preferred		(111,837	)		(35,788	)		(8,687,630	)		(4,892,873	)		—			—			(10,586,174	)		(979,070	)		2,985,863			4,030,920			—			—			—			—
	Reduction of liquidation value		—			(783,396	)		—			(18,001,661	)		—			—			—			(6,195,373	)		—			—			—			—			—			—
	Stock issuance costs		—			—			—			—			—			—			—			—			—			(64,530	)		—			—			—			(556,247	)
	Reversal of prior accretion		—			—			—			(4,128,742	)		—			—			—			(1,528,896	)		—			—			—			—			—			—
	Accretion		—			—			—			—			—			—			—			74,152			—			706,902			—			10,752			—			92,841
	Balance as of December 31, 2013		1,040,216			332,869			9,803,688			5,521,437			—			—			28,716,679			2,655,884			21,040,817			33,262,492			—			—			56,011,258			71,891,787
	Accretion		—			—			—			—			—			—			—			—			—			336,350			—			—			—			526,876
	Shares converted to common stock		(1,040,216	)		(332,869	)		(9,803,688	)		(5,521,437	)		—			—			(28,716,679	)		(2,655,884	)		(21,040,817	)		(33,598,842	)		—			—			(56,011,258	)		(72,418,423	)
	Stock issuance costs		—			—			—			—			—			—			—			—			—			—			—			—			—			(240	)
	Balance as of December 31, 2014		—		$	—			—		$	—			—		$	—			—		$	—			—		$	—			—		$	—			—		$	—

Note_11_Warrants_Tables

Note 11 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Warrants [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Type of Warrant	Number of Shares		Exercise Price		Expiration
						Date(s)
	Common		1	$	23,894.34	7/13/16
	Common		9,598	$	6.6	12/20/23
	Type of Warrant	Number of Shares		Exercise Price		Expiration
						Date(s)
	Common stock		1	$	23,894.34	7/13/16
	Common stock		82,780	$	9.06	9/29/21

Note_12_Stock_Options_and_Empl1

Note 12 - Stock Options and Employee Stock Purchase Plan (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]			Years Ended December 31,
			2012				2013				2014
	Research and development		$	511,860			$	524,495			$	1,604,215
	General and administrative			531,129				528,668				1,409,068
	Total stock-based compensation expense		$	1,042,989			$	1,053,163			$	3,013,283
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]			2012				2013				2014
	Risk-free interest rate			1.2	%			2.12	%			2.26	%
	Expected dividend yield			0	%			0	%			0	%
	Expected option term (in years)			7				7				7
	Expected volatility			94	%			94	%			96	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]			Number of				Weighted				Weighted				Aggregate
			Shares				Average Exercise				Average				Intrinsic
							Price				Contractual				Value
											Term
											(in years)
	Outstanding as of December 31, 2013			1,957,069			$	5.48
	Granted			967,903			$	6.7
	Exercised			(3,050	)		$	4.2
	Cancelled			(74,825	)		$	4.94
	Outstanding as of December 31, 2014			2,847,097			$	5.89				8.65			$	11,796,921
	Exercisable as of December 31, 2014			897,294			$	5.04				7.54			$	4,509,931
	Vested and expected to vest as of December 31, 2014			2,716,363			$	5.86				8.62			$	11,255,225
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Exercise Price or Range of Exercise Price				Options Outstanding				Weighted Average				Options Exercisable
									Contractual Life
									(Years)
		$4.20				553,434				6.64				521,718
		$5.82				1,219,689				8.85				333,785
	$5.98	to	$6.62			869,525				9.5				—
	$7.32	to	$11.09			203,172				9.1				40,514
	$35.30	to	$36.66			1,271				6.7				1,271
	$135.78	to	$4,615.92			6				0.83				6
						2,847,097				8.65				897,294

Note_16_Facility_Lease_Obligat1

Note 16 - Facility Lease Obligation (Tables)	12 Months Ended
	Dec. 31, 2014
Note 16 - Facility Lease Obligation (Tables) [Line Items]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2015	$	394,089
	2016		435,359
	2017		79,688
	Total minimum lease payments	$	909,136
Facility Lease [Member]
Note 16 - Facility Lease Obligation (Tables) [Line Items]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year ending December 31:
	2015	$	375,333
	2016		571,445
	2017		584,303
	2018		597,449
	2019		610,892
	Thereafter		3,496,201
	Total future minimum lease payments	$	6,235,623

Note_18_Commitments_Tables

Note 18 - Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2015	$	394,089
	2016		435,359
	2017		79,688
	Total minimum lease payments	$	909,136

Note_20_Net_Loss_Per_Share_Tab

Note 20 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Year Ended December 31,
		2012			2013			2014
	Net loss	$	(10,471,330	)	$	(23,921,563	)	$	(53,305,938	)
	Accretion of redeemable convertible preferred stock		(351,371	)		(884,647	)		(863,226	)
	Reverse prior accretion on redeemable preferred stock due to reduction in liquidation value of Series A, B, and C		—			5,657,638			—
	Preferred stock dividend due to exchanges of preferred shares		—			(14,726,088	)		—
	Net loss attributable to common stockholders	$	(10,822,701	)	$	(33,874,660	)	$	(54,169,164	)
	Weighted average common shares outstanding, basic and diluted		198,306			229,865			17,367,665
	Net loss per share attributable to common stockholders, basic and diluted	$	(54.58	)	$	(147.37	)	$	(3.12	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		Year Ended December 31,
		2012			2013			2014
	Redeemable convertible preferred stock		2,167,143			6,322,747			—
	Stock options outstanding		366,389			767,510			2,847,097
	Warrants outstanding		316,184			424,961			82,781

Note_21_Selected_Quarterly_Dat1

Note 21 - Selected Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2014			2014			2014			2014
	Revenue	$	798,788		$	473,163		$	398,615		$	303,453
	Operating expenses:
	Research and development		8,472,195			10,569,134			12,998,409			13,459,178
	General and administrative		1,933,476			1,865,822			2,320,036			2,480,025
	Operating loss		(9,606,883	)		(11,961,793	)		(14,919,830	)		(15,635,750	)
	Other income (expense), net		(394,097	)		(21,738	)		(181,187	)		(584,660	)
	Net loss		(10,000,980	)		(11,983,531	)		(15,101,017	)		(16,220,410	)
	Accretion of redeemable convertible preferred stock		(863,226	)		—			—			—
	Less: Preferred stock dividend due to exchanges of preferred shares		-			-			-			-
	Net loss attributable to common stockholders	$	(10,864,206	)	$	(11,983,531	)	$	(15,101,017	)	$	(16,220,410	)
	Net loss attributable to common stockholders per share, basic and diluted	$	(1.05	)	$	(0.61	)	$	(0.77	)	$	(0.83	)
	Weighted average shares outstanding, basic and diluted		10,376,561			19,655,187			19,655,561			19,656,209
		Quarter Ended
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Revenue	$	1,461,687		$	1,263,008		$	981,247		$	715,747
	Operating expenses:
	Research and development		5,189,461			6,102,320			5,630,219			7,069,151
	General and administrative		1,078,357			939,725			1,024,167			1,620,068
	Operating loss		(4,806,131	)		(5,779,037	)		(5,673,139	)		(7,973,472	)
	Other income (expense), net		356,929			196			541			(47,450	)
	Net loss		(4,449,202	)		(5,778,841	)		(5,672,598	)		(8,020,922	)
	Accretion of redeemable convertible preferred stock		(64,940	)		(10,446	)		5,325,406			(477,029	)
	Less: Preferred stock dividend due to exchanges of preferred shares		—			—			(14,726,088	)		—
	Net loss attributable to common stockholders	$	(4,514,142	)	$	(5,789,287	)	$	(15,073,280	)	$	(8,497,951	)
	Net loss attributable to common stockholders per share, basic and diluted	$	(19.91	)	$	(25.53	)	$	(65.23	)	$	(36.19	)
	Weighted average shares outstanding, basic and diluted		226,757			226,757			231,084			234,789

Note_1_Organization_Details

Note 1 - Organization (Details) (USD $)	1 Months Ended		12 Months Ended
	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 02, 2014
Note 1 - Organization (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)		6,228,725
Share Price (in Dollars per share)		$8	$10			$9.83
Proceeds from Issuance Initial Public Offering		$49,800,000	$49,829,800
Payments of Stock Issuance Costs			4,875,404	1,501,344	208,934
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)		13,188,251
Payments for Fees	200,000	200,000
Underwriting Discounts and Commissions [Member]
Note 1 - Organization (Details) [Line Items]
Payments of Stock Issuance Costs		3,500,000
Other Offering Expenses [Member]
Note 1 - Organization (Details) [Line Items]
Payments of Stock Issuance Costs		2,900,000
Other Expense [Member]
Note 1 - Organization (Details) [Line Items]
Payments for Fees	200,000
Net of Discounts and Commissions [Member]
Note 1 - Organization (Details) [Line Items]
Proceeds from Issuance Initial Public Offering		$43,400,000
Additional Shares [Member]
Note 1 - Organization (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)		603,725

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended			18 Months Ended	3 Months Ended	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2012	Sep. 30, 2012
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Cash, Uninsured Amount	$36,973,590	$33,047,970		$36,973,590
Derivative, Number of Instruments Held	0	0	0	0	0
Royalty Revenue				0
Number of Operating Segments	1
Other Receivables, Net, Current	129,019	424,501		129,019
Other Income	140,556	0	694,331
Derivative Asset	0	0		0
Derivative Liability	0	0		0
Operating Expense [Member] | NIH & NIAID [Member] | Initial [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Unattained Funds, Contracted Commitment	38,400,000			38,400,000
Other Specified [Member] | NIH & NIAID [Member] | Initial [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Unattained Funds, Contracted Commitment	1,400,000			1,400,000
Other Specified [Member] | NIH [Member] | Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Unattained Funds, Contracted Commitment	1,400,000			1,400,000
NIH & NIAID [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Unattained Funds, Contracted Commitment	$39,800,000			$39,800,000
DC Bio [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage			100.00%		100.00%	49.94%

Note_3_Fair_Value_of_Financial2

Note 3 - Fair Value of Financial Instruments (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Long-term Debt, Fair Value	$19.40	$7
Long-term Debt	19.8
Preferred Stock [Member]
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Warrants and Rights Outstanding	0	0
Fair Value, Inputs, Level 3 [Member]
Note 3 - Fair Value of Financial Instruments (Details) [Line Items]
Assets, Fair Value Disclosure	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$0

Note_3_Fair_Value_of_Financial3

Note 3 - Fair Value of Financial Instruments (Details) - Fair Value of Financial Instruments (USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets
Short-term investments	$19,016,347	$13,659,812
Total assets at fair value	57,132,838
Restricted cash – long-term	1,325,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Money-market funds	35,541,595	22,891,418
Money Market Funds [Member]
Assets
Money-market funds	35,541,595	22,891,418
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Total assets at fair value		22,891,418
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Short-term investments	20,266,243	13,659,812
Total assets at fair value		13,659,812
Corporate Debt Securities [Member]
Assets
Short-term investments	20,266,243	13,659,812
Total assets at fair value		36,551,230
Fair Value, Inputs, Level 1 [Member]
Assets
Total assets at fair value	36,866,595
Restricted cash – long-term	1,325,000
Fair Value, Inputs, Level 2 [Member]
Assets
Total assets at fair value	$20,266,243

Note_3_Fair_Value_of_Financial4

Note 3 - Fair Value of Financial Instruments (Details) - Changes in Balance of Level 3 Liabilities (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance		$6,392,652
Net Change in Unrealized (Gains) Losses	-355,352
Reduction	-6,037,300
Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance		6,392,652
Net Change in Unrealized (Gains) Losses	-355,352
Reduction	($6,037,300)

Note_4_Property_and_Equipment_1

Note 4 - Property and Equipment (Details) - Property and Equipment (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Balance	$13,749,884	$9,766,135
Less: Accumulated depreciation and amortization	-8,236,329	-8,164,032
Property and equipment, net	5,513,555	1,602,103
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	7 years
Balance	458,380	528,732
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Balance	788,563	712,609
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Balance	629,948	540,809
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	7 years
Balance	5,345,786	5,264,952
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	5 years
Balance	2,646,891	2,643,023
Assets Held under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Balance	3,380,223
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Balance	$500,093	$76,010

Note_4_Property_and_Equipment_2

Note 4 - Property and Equipment (Details) - Depreciation and Amortization Expense (USD $)	0 Months Ended			12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Depreciation and Amortization Expense [Abstract]
Depreciation and amortization expense	$566,117	$611,421	$505,261	$566,117	$611,421	$505,261

Note_5_Noncontrolling_Interest1

Note 5 - Noncontrolling Interest (Details) (DC Bio [Member])	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2012
DC Bio [Member]
Note 5 - Noncontrolling Interest (Details) [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	100.00%	49.94%	100.00%

Note_6_Income_Taxes_Details

Note 6 - Income Taxes (Details) (USD $)	12 Months Ended				0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 23, 2013	Jan. 01, 2014
Note 6 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	$0		$0	$0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	20,252,063
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%	34.00%	34.00%
Effective Income Tax Rate Reconciliation, Percent	0.00%		0.00%	0.00%
Unrecognized Tax Benefits	2,155,000	1,644,500	1,265,700	1,272,800		1,644,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	0	0
Tax Year 2012 [Member] | Research Tax Credit Carryforward [Member]
Note 6 - Income Taxes (Details) [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		298,000
Tax Year 2013 [Member] | Research Tax Credit Carryforward [Member]
Note 6 - Income Taxes (Details) [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		585,700
Tax Year 2013 [Member]
Note 6 - Income Taxes (Details) [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount					-1,349,100
Effective Income Tax Rate Reconciliation, Percent					6.90%
Tax Year 2014 [Member]
Note 6 - Income Taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, Percent					6.00%
Tax Year 2015 [Member]
Note 6 - Income Taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, Percent					5.00%
Domestic Tax Authority [Member]
Note 6 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	158,406,400
Tax Credit Carryforward, Amount	5,028,400
State and Local Jurisdiction [Member]
Note 6 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	176,699,700
Tax Credit Carryforward, Amount	340,400
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Note 6 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	6,579,600
Tax Credit Carryforward, Amount	35,100
Foreign Tax Authority [Member] | Canadian Provincial [Member]
Note 6 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	6,579,600
DC Bio [Member]
Note 6 - Income Taxes (Details) [Line Items]
Undistributed Earnings of Foreign Subsidiaries	$0

Note_6_Income_Taxes_Details_Si

Note 6 - Income Taxes (Details) - Significant Components of Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
Significant Components of Deferred Tax Assets and Liabilities [Abstract]
U.S. federal and state net operating loss carryforwards	$59,689,264	$41,359,722
Foreign net operating loss carryforwards	1,743,603	1,827,221
Contribution carryforwards	4,245	3,055
Research and development credits	5,253,055	4,061,844
Investment tax credits	35,108	38,175
Stock-based compensation	462,796	22,282
Patents and other intangibles	611	2,967
Other accruals	125,614	97,157
Deferred revenue	372,040
Property and equipment	510,466	532,316
Total deferred tax assets	68,196,802	47,944,739
Valuation allowance for deferred assets	-68,196,802	-47,944,739
Net deferred tax assets	$0	$0

Note_6_Income_Taxes_Details_Ef

Note 6 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Effective Income Tax Rate Reconciliation [Abstract]
U.S. federal tax statutory rate (in Dollars)	($18,124,019)		($8,133,331)	($3,560,252)
U.S. federal tax statutory rate	34.00%	34.00%	34.00%	34.00%
State taxes (net of federal benefit) (in Dollars)	-1,707,912		-789,412	-476,446
State taxes (net of federal benefit)	3.20%		3.30%	4.50%
U.S. federal research and development tax credits (in Dollars)	-1,701,727		-1,262,562
U.S. federal research and development tax credits	3.20%		5.30%	0.00%
Nondeductible interest expense (in Dollars)			-132,546	-1,782,830
Nondeductible interest expense	0.00%		0.60%	17.00%
Other nondeductible expenses (in Dollars)	658,740		419,934	-210,790
Other nondeductible expenses	-1.10%		-1.80%	2.00%
Expiration of capital loss carryforward (in Dollars)				3,246,049
Expiration of capital loss carryforward	0.00%		0.00%	-31.00%
Increase in unrecognized tax benefits (in Dollars)	510,516		378,769
Increase in unrecognized tax benefits	-1.00%		-1.60%	0.00%
Change in effective state tax rate (in Dollars)	1,685		1,349,062
Change in effective state tax rate	0.00%		-5.60%	0.00%
Expiration of NOL & contribution carryforwards (in Dollars)	77,391		6,630	57,538
Expiration of NOL & contribution carryforwards	-0.10%		0.00%	-0.50%
Change in valuation reserves (in Dollars)	20,252,063		8,811,127	2,618,552
Change in valuation reserves	-38.10%		-36.80%	-25.20%
Deferred tax asset true-ups (in Dollars)	33,263		-647,671	108,179
Deferred tax asset true-ups	-0.10%		2.60%	-0.80%
Provision for income taxes (in Dollars)	$0		$0	$0
Provision for income taxes	0.00%		0.00%	0.00%

Note_6_Income_Taxes_Details_Ch

Note 6 - Income Taxes (Details) - Change in Gross Unrecognized Tax Position (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Change in Gross Unrecognized Tax Position [Abstract]
Beginning balance	$1,644,500	$1,265,700	$1,272,800
Gross increase for tax positions related to current periods	474,300	378,800
Gross (decrease) increase for tax positions related to prior periods			-7,100
Gross (decrease) increase for tax positions related to prior periods	36,200
Ending balance	$2,155,000	$1,644,500	$1,265,700

Note_7_Convertible_Term_Notes_

Note 7 - Convertible Term Notes (Details) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2012	Apr. 10, 2012	Sep. 09, 2010	Dec. 15, 2010	Jul. 27, 2011	Dec. 31, 2010
Note 7 - Convertible Term Notes (Details) [Line Items]
Debt Conversion, Original Debt, Amount	$10,668,185
Series D Preferred Stock [Member] | The 2010 Convertible Notes and July 2011 Convertible Notes [Member]
Note 7 - Convertible Term Notes (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		3,023,661
The 2010 Convertible Notes [Member]
Note 7 - Convertible Term Notes (Details) [Line Items]
Convertible Debt			6,000,000
Number of Tranches			2
Debt Instrument, Interest Rate, Stated Percentage						10.00%
Convertible Debt, Fair Value Disclosures						6,603,333
Interest Expense, Debt	193,402
The 2010 Convertible Debt and Warrants [Member] | Tranche 1 [Member]
Note 7 - Convertible Term Notes (Details) [Line Items]
Proceeds from Convertible Debt and Warrants			4,872,066
The 2010 Convertible Debt and Warrants [Member] | Tranche 2 [Member]
Note 7 - Convertible Term Notes (Details) [Line Items]
Proceeds from Convertible Debt and Warrants				1,127,925
July 2011 Convertible Notes [Member]
Note 7 - Convertible Term Notes (Details) [Line Items]
Convertible Debt					3,500,000
Debt Instrument, Interest Rate, Stated Percentage					10.00%
Convertible Debt, Fair Value Disclosures					3,686,250
Interest Expense, Debt	98,662
July 2011 Convertible Notes and Warrants [Member]
Note 7 - Convertible Term Notes (Details) [Line Items]
Proceeds from Convertible Debt and Warrants					3,500,000
The 2010 Convertible Notes and July 2011 Convertible Notes [Member]
Note 7 - Convertible Term Notes (Details) [Line Items]
Interest Expense, Debt	292,064
Debt Conversion, Original Debt, Amount		10,668,185

Note_8_Notes_Payable_Details

Note 8 - Notes Payable (Details) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Sep. 29, 2014	Dec. 31, 2013	Nov. 30, 2013	Jul. 31, 2012
Note 8 - Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	9,598		9,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$6.60		$6.60
Notes Payable	$19,827,430		$7,059,553
Deferred Credits and Other Liabilities, Noncurrent	3,066,000		3,066,000
Debt Instrument, Increase, Accrued Interest	693,114
Primary Payment Period [Member] | Venture Loan And Security Agreement [Member] | Secondary Tranche [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Term	18 months
Secondary Payment Period [Member] | Venture Loan And Security Agreement [Member] | Secondary Tranche [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Term	24 months
Pre Payment On Or Before Twenty Four Months Of Funding Date [Member] | Venture Loan And Security Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument Pre Payment PenaltyPercentageOfBalance	3.00%
Pre Payment After Twenty Four Months But On Or Before Thirty Six Months [Member] | Venture Loan And Security Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument Pre Payment PenaltyPercentageOfBalance	2.00%
Pre Payment After Thirty Six Months Of Funding Date [Member] | Venture Loan And Security Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument Pre Payment PenaltyPercentageOfBalance	1.00%
Unrestricted Warrants [Member] | Venture Loan And Security Agreement [Member] | Maximum [Member]
Note 8 - Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		41,390
Unrestricted Warrants [Member]
Note 8 - Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		41,390
Manufacturing License [Member] | December 2013 Note [Member]
Note 8 - Notes Payable (Details) [Line Items]
Deferred Credits and Other Liabilities, Noncurrent	1,000,000
Venture Loan And Security Agreement [Member] | Primary Tranche [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument Tranche Amount		12,500,000
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid		625,000
Venture Loan And Security Agreement [Member] | Secondary Tranche [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument Tranche Amount	12,500,000
Debt Instrument, Term	42 months
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid As A Percentage	5.00%
Venture Loan And Security Agreement [Member] | LIBOR Rate In Excess Of A Half A Percent [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate		9.25%
Venture Loan And Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate		8.75%
Venture Loan And Security Agreement [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount		25,000,000
Loan Facility Number Of Tranches		2
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum		10.75%
Debt Related Commitment Fees and Debt Issuance Costs		449,796
Debt Instrument Interest Rate Increase On Default		5.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		82,780
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		9.06
Debt Instrument, Unamortized Discount		338,673
December 2013 Note [Member]
Note 8 - Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount			9,000,000
Proceeds from Notes Payable			9,000,000
Debt Instrument, Interest Rate, Stated Percentage			3.00%
Notes Payable	7,623,546		6,936,466
Debt Instrument, Interest Rate, Effective Percentage			8.00%
Deferred Credits and Other Liabilities, Noncurrent	3,100,000		2,100,000
Debt Instrument, Increase, Accrued Interest	700,000
July 2012 Note [Member]
Note 8 - Notes Payable (Details) [Line Items]
Proceeds from Notes Payable	95,756
Debt Instrument, Interest Rate, Stated Percentage	0.98%
Notes Payable	16,356		48,429
Line of Credit Facility, Maximum Borrowing Capacity					100,000
Debt Instrument, Number of Payments	36
November 2013 Note [Member]
Note 8 - Notes Payable (Details) [Line Items]
Proceeds from Notes Payable				77,832
Debt Instrument, Interest Rate, Stated Percentage	8.31%
Notes Payable	$61,284		$74,658
Debt Instrument, Number of Payments	60

Note_8_Notes_Payable_Details_N

Note 8 - Notes Payable (Details) - Notes Payable (USD $)	Dec. 31, 2014	Dec. 31, 2013
Note 8 - Notes Payable (Details) - Notes Payable [Line Items]
Notes Payable	$19,827,430	$7,059,553
Less current portion	-30,885	-45,447
Long-term portion of notes payable	19,796,545	7,014,106
December 2013 Note [Member]
Note 8 - Notes Payable (Details) - Notes Payable [Line Items]
Notes Payable	7,623,546	6,936,466
July 2012 Note [Member]
Note 8 - Notes Payable (Details) - Notes Payable [Line Items]
Notes Payable	16,356	48,429
Other notes payable	77,640	123,087
Horizon And Fortress Lenders [Member]
Note 8 - Notes Payable (Details) - Notes Payable [Line Items]
Notes payable under the venture loan and security agreement	12,500,000
Less related debt discount	-373,756
Notes Payable	$12,126,244

Note_9_Derivatives_Details

Note 9 - Derivatives (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Oct. 01, 2012
Note 9 - Derivatives (Details) [Line Items]
Derivative Liability	$0	$0
Series C Preferred Stock [Member] | DC Bio [Member]
Note 9 - Derivatives (Details) [Line Items]
Preferred Stock, Capital Shares Reserved for Future Issuance (in Shares)			652,608
Series B Preferred Stock [Member] | DC Bio [Member]
Note 9 - Derivatives (Details) [Line Items]
Preferred Stock, Capital Shares Reserved for Future Issuance (in Shares)			419,768
Common Stock [Member] | DC Bio [Member]
Note 9 - Derivatives (Details) [Line Items]
Preferred Stock, Capital Shares Reserved for Future Issuance (in Shares)			23,703
DC Bio [Member]
Note 9 - Derivatives (Details) [Line Items]
Derivative Liability			1,036,403
Business Transaction Fair Value of Shares Issuable on Option Exercise			1,487,668
Business Transaction Fair Value of Exchangeable Shares			451,265
Proceeds from Disposal of Non-controlling Interest				$180,000

Note_10_Common_Stock_Redeemabl2

Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) (USD $)	1 Months Ended	12 Months Ended			1 Months Ended
	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2013	Apr. 30, 2012	Aug. 31, 2012	Nov. 30, 2013	Oct. 31, 2013	Aug. 31, 2013	Sep. 02, 2014
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Common Stock, Shares Authorized		200,000,000	120,000,000
Temporary Equity, Shares Authorized		0	160,700,000
Preferred Stock, Shares Authorized		5,000,000	0
Stock Issued During Period, Shares, New Issues	6,228,725
Share Price (in Dollars per share)	$8	$10									$9.83
Proceeds from Issuance Initial Public Offering (in Dollars)	$49,800,000	$49,829,800
Payments of Stock Issuance Costs (in Dollars)		4,875,404	1,501,344	208,934
Temporary Equity, Shares Outstanding		0
Preferred Stock, Shares Issued		0	0
Stock Issued During Period, Value, New Issues (in Dollars)		49,829,800
Debt Conversion, Original Debt, Amount (in Dollars)				10,668,185
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		9,598	9,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$6.60	$6.60
Underwriting Discounts and Commissions [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Payments of Stock Issuance Costs (in Dollars)	3,500,000
Other Offering Expenses [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Payments of Stock Issuance Costs (in Dollars)	2,900,000
Series D Redeemable Convertible Preferred Stock [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			6,373,782	2,549,897	6,373,782
Temporary Equity, Shares Outstanding			21,040,817	8,137,739
Stock Issued During Period, Value, New Issues (in Dollars)			11,446,143	4,793,806		19,700,000
Debt Conversion, Original Debt, Amount (in Dollars)						10,700,000
Conversion of Stock, Shares Converted		21,040,817
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)					$1.98
Series D-1 Redeemable Convertible Preferred Stock [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				3,713,333			3,716,935
Share Price (in Dollars per share)							$4.30
Temporary Equity, Shares Outstanding				7,433,870
Stock Issued During Period, Value, New Issues (in Dollars)				7,842,733			16,000,000
Series E Redeemable Convertible Preferred Stock [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			36,856,922					19,037,063	921,423	16,898,436
Temporary Equity, Shares Outstanding			56,011,258
Stock Issued During Period, Value, New Issues (in Dollars)			47,409,867					24,792,595	1,200,000	22,007,404
Conversion of Stock, Shares Converted		56,011,258
Preferred Stock [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Preferred Stock, Shares Issued		0
Conversion of Redeemable Convertible Preferred Stock to Common Stock [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Conversion of Stock, Shares Issued	13,188,251
Conversion of Series D-1 Preferred Stock to Series D Preferred Stock [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Conversion of Stock, Shares Issued					16,151,212
Conversion of Stock, Shares Converted					7,433,870
Net of Discounts and Commissions [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Proceeds from Issuance Initial Public Offering (in Dollars)	$43,400,000
Additional Shares [Member]
Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	603,725

Note_10_Common_Stock_Redeemabl3

Note 10 - Common Stock, Redeemable Convertible Preferred Stock and Preferred Stock (Details) - Preferred Stock (USD $)	1 Months Ended	12 Months Ended			1 Months Ended
	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2013	Apr. 30, 2012	Aug. 31, 2012	Nov. 30, 2013	Oct. 31, 2013	Aug. 31, 2013
Class of Stock [Line Items]
Exchange of Stock			$14,726,088
Issuance of shares (in Shares)	6,228,725
Issuance of shares		49,829,800
Reduction of liquidation value			24,980,430
Shares converted to common stock		-114,527,695		-8,067,307
Balance, shares (in Shares)		0
Series A Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Balance, shares (in Shares)		1,040,216	1,152,053	1,276,103
Balance		332,869	1,152,053	1,276,103
Pull through of existing preferred (in Shares)			-111,837
Pull through of existing preferred			-35,788
Reduction of liquidation value			-783,396
Shares converted to common stock (in Shares)		-1,040,216		-124,050
Shares converted to common stock		-332,869		-124,050
Balance, shares (in Shares)			1,040,216	1,152,053
Balance			332,869	1,152,053
Series B Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Balance, shares (in Shares)		9,803,688	18,491,318	24,326,574
Balance		5,521,437	32,544,713	42,814,762
Pull through of existing preferred (in Shares)			-8,687,630	-3,652,680
Pull through of existing preferred			-4,892,873	-6,428,717
Reduction of liquidation value			-18,001,661
Reversal of prior accretion			-4,128,742
Shares converted to common stock (in Shares)		-9,803,688		-2,182,576
Shares converted to common stock		-5,521,437		-3,841,332
Balance, shares (in Shares)			9,803,688	18,491,318
Balance			5,521,437	32,544,713
Series B-1 Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Balance, shares (in Shares)				917,771
Balance				1,615,276
Shares converted to common stock (in Shares)				-917,771
Shares converted to common stock				-1,615,276
Series C Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Balance, shares (in Shares)		28,716,679	39,302,853	112,165,271
Balance		2,655,884	11,285,071	32,016,165
Pull through of existing preferred (in Shares)			-10,586,174	-64,256,463
Pull through of existing preferred			-979,070	-18,571,283
Reduction of liquidation value			-6,195,373
Reversal of prior accretion			-1,528,896
Shares converted to common stock (in Shares)		-28,716,679		-8,605,955
Shares converted to common stock		-2,655,884		-2,487,276
Accretion			74,152	327,465
Balance, shares (in Shares)			28,716,679	39,302,853
Balance			2,655,884	11,285,071
Series D Redeemable Convertible Preferred Stock [Member] | Exchange of Series D-1 [Member]
Class of Stock [Line Items]
Exchange of Stock (in Shares)			16,151,212
Exchange of Stock			26,887,407
Series D Redeemable Convertible Preferred Stock [Member] | Exchange of Series D [Member]
Class of Stock [Line Items]
Exchange of Stock (in Shares)			-12,607,779
Exchange of Stock			-24,945,326
Series D Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Balance, shares (in Shares)		21,040,817	8,137,739
Balance		33,262,492	15,200,976
Issuance of shares (in Shares)			6,373,782	2,549,897	6,373,782
Issuance of shares			11,446,143	4,793,806		19,700,000
Conversion of bridge note (in Shares)				3,023,661
Conversion of bridge note				5,684,483
Conversion of accrued services (in Shares)				7,142
Conversion of accrued services				25,200
Pull through of existing preferred (in Shares)			2,985,863	2,557,039
Pull through of existing preferred			4,030,920	4,807,233
Stock issuance costs			-64,530	-128,275
Shares converted to common stock (in Shares)		-21,040,817
Shares converted to common stock		-33,598,842
Accretion		336,350	706,902	18,529
Balance, shares (in Shares)			21,040,817	8,137,739
Balance			33,262,492	15,200,976
Series D-1 Redeemable Convertible Preferred Stock [Member] | Exchange of Series D-1 [Member]
Class of Stock [Line Items]
Exchange of Stock (in Shares)			-7,433,870
Exchange of Stock			-15,628,821
Series D-1 Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Balance, shares (in Shares)			7,433,870
Balance			15,618,069
Issuance of shares (in Shares)				3,713,333			3,716,935
Issuance of shares				7,842,733			16,000,000
Conversion of accrued services (in Shares)				3,602
Conversion of accrued services				15,485
Pull through of existing preferred (in Shares)				3,716,935
Pull through of existing preferred				7,835,133
Stock issuance costs				-80,659
Accretion			10,752	5,377
Balance, shares (in Shares)				7,433,870
Balance				15,618,069
Series E Redeemable Convertible Preferred Stock [Member] | Exchange of Series D [Member]
Class of Stock [Line Items]
Exchange of Stock (in Shares)			19,154,336
Exchange of Stock			24,945,326
Series E Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Balance, shares (in Shares)		56,011,258
Balance		71,891,787
Issuance of shares (in Shares)			36,856,922					19,037,063	921,423	16,898,436
Issuance of shares			47,409,867					24,792,595	1,200,000	22,007,404
Stock issuance costs		-240	-556,247
Shares converted to common stock (in Shares)		-56,011,258
Shares converted to common stock		-72,418,423
Accretion		526,876	92,841
Balance, shares (in Shares)			56,011,258
Balance			$71,891,787

Note_11_Warrants_Details

Note 11 - Warrants (Details) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Nov. 30, 2013	Dec. 31, 2013	Sep. 29, 2014
Note 11 - Warrants (Details) [Line Items]
Class of Warrant or Right, Outstanding			9,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	6.6		$6.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	9,598		9,598
Settlement of Warrants [Member]
Note 11 - Warrants (Details) [Line Items]
Conversion of Stock, Shares Issued	1,679
Warrant One [Member]
Note 11 - Warrants (Details) [Line Items]
Class of Warrant or Right, Outstanding	1		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	23,894.34		$23,894.34	$23,894.34
Unrestricted Warrants [Member]
Note 11 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				41,390
Scenario, Plan [Member] | Pharmstandard [Member]
Note 11 - Warrants (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		5.82
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		499,788
Lenders and Affiliates [Member]
Note 11 - Warrants (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$9.06
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				82,780
Pharmstandard [Member]
Note 11 - Warrants (Details) [Line Items]
Conversion of Stock, Shares Issued		13,188,251

Note_11_Warrants_Details_Outst

Note 11 - Warrants (Details) - Outstanding Warrants (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 29, 2014
Class of Warrant or Right [Line Items]
Number of warrants		9,598
Exercise price	$6.60	$6.60
Warrant One [Member]
Class of Warrant or Right [Line Items]
Number of warrants	1	1
Exercise price	$23,894.34	$23,894.34	$23,894.34
Expiration dates	13-Jul-16	13-Jul-16
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Number of warrants	82,780	9,598
Exercise price	$9.06	$6.60
Expiration dates	29-Sep-21	20-Dec-23

Note_12_Stock_Options_and_Empl2

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) (USD $)

1 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

Mar. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Jul. 28, 2014

Sep. 30, 2014

Sep. 02, 2014

Feb. 28, 2014

Feb. 12, 2014

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Share Price (in Dollars per share)

$10

$9.83

$8

Common Stock, Capital Shares Reserved for Future Issuance

4,200,717

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)

$10.86

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit (in Dollars per share)

$36.66

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

201,000

967,903

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$4.20

$6.70

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

0.00%

0.00%

Allocated Share-based Compensation Expense (in Dollars)

$3,013,283

$1,053,163

$1,042,989

Initial Authorization [Member] | The 2014 Plan [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

1,951,182

Additional Authorization [Member] | The 2014 Plan [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

357,841

Employee Stock Option [Member] | Scenario, Forecast [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Allocated Share-based Compensation Expense (in Dollars)

548,189

2,427,924

2,898,537

3,069,553

Employee Stock Option [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

8,944,203

Employee and Non-Employee Director [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

160,500

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$6.09

The 2014 Plan [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

2,309,023

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percent of Shares Outstanding

4.00%

The 2008 Plan [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

381,250

The 2014 ESPP [Member]

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate

10.00%

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

85.00%

Employee Stock Purchase Plan (ESPP), Number of Shares Allocated

9,000

Common Stock, Capital Shares Reserved for Future Issuance

346,353

Employee Service Share-based Compensation, Tax Benefit from Compensation Expense (in Dollars)

$0

Note_12_Stock_Options_and_Empl3

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) - Stock-based Compensation Expense (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$3,013,283	$1,053,163	$1,042,989
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	1,604,215	524,495	511,860
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$1,409,068	$528,668	$531,129

Note_12_Stock_Options_and_Empl4

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) - Stock Option Valuation Assumptions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option Valuation Assumptions [Abstract]
Risk-free interest rate	2.26%	2.12%	1.20%
Expected dividend yield	0.00%	0.00%	0.00%
Expected option term (in years)	7 years	7 years	7 years
Expected volatility	96.00%	94.00%	94.00%

Note_12_Stock_Options_and_Empl5

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) - Stock Option Activity (USD $)	1 Months Ended	12 Months Ended
	Mar. 31, 2012	Dec. 31, 2014
Stock Option Activity [Abstract]
Outstanding as of December 31, 2013		1,957,069
Outstanding as of December 31, 2013		$5.48
Granted	201,000	967,903
Granted	$4.20	$6.70
Exercised		-3,050
Exercised		$4.20
Cancelled		-74,825
Cancelled		$4.94
Outstanding as of December 31, 2014		2,847,097
Outstanding as of December 31, 2014		$5.89
Outstanding as of December 31, 2014		8 years 237 days
Outstanding as of December 31, 2014		$11,796,921
Exercisable as of December 31, 2014		897,294
Exercisable as of December 31, 2014		$5.04
Exercisable as of December 31, 2014		7 years 197 days
Exercisable as of December 31, 2014		4,509,931
Vested and expected to vest as of December 31, 2014		2,716,363
Vested and expected to vest as of December 31, 2014		$5.86
Vested and expected to vest as of December 31, 2014		8 years 226 days
Vested and expected to vest as of December 31, 2014		$11,255,225

Note_12_Stock_Options_and_Empl6

Note 12 - Stock Options and Employee Stock Purchase Plan (Details) - Summary of Stock Options (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2011	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exericse price range, lower limit (in Dollars per share)		$10.86
Exercise price (in Dollars per share)	$5.89		$5.48
Exercise price range, upper limit (in Dollars per share)		$36.66
Options outstanding	2,847,097		1,957,069
Weighted average contractual life	8 years 237 days
Options exercisable	897,294
Exercise Price Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in Dollars per share)	$4.20
Options outstanding	553,434
Weighted average contractual life	6 years 233 days
Options exercisable	521,718
Exercise Price Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in Dollars per share)	$5.82
Options outstanding	1,219,689
Weighted average contractual life	8 years 310 days
Options exercisable	333,785
Exercise Price Range 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exericse price range, lower limit (in Dollars per share)	$5.98
Exercise price range, upper limit (in Dollars per share)	$6.62
Options outstanding	869,525
Weighted average contractual life	9 years 6 months
Exercise Price Range 4 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exericse price range, lower limit (in Dollars per share)	$7.32
Exercise price range, upper limit (in Dollars per share)	$11.09
Options outstanding	203,172
Weighted average contractual life	9 years 36 days
Options exercisable	40,514
Exercise Price Range 5 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exericse price range, lower limit (in Dollars per share)	$35.30
Exercise price range, upper limit (in Dollars per share)	$36.66
Options outstanding	1,271
Weighted average contractual life	6 years 255 days
Options exercisable	1,271
Exercise Price Range 6 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exericse price range, lower limit (in Dollars per share)	$135.78
Exercise price range, upper limit (in Dollars per share)	$4,615.92
Options outstanding	6
Weighted average contractual life	302 days
Options exercisable	6

Note_13_Revenue_and_Concentrat1

Note 13 - Revenue and Concentration of Credit Risk (Details) (USD $)	3 Months Ended								12 Months Ended			100 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Sep. 18, 2014
Note 13 - Revenue and Concentration of Credit Risk (Details) [Line Items]
Revenues	$303,453	$398,615	$473,163	$798,788	$715,747	$981,247	$1,263,008	$1,461,687	$1,974,019	$4,421,689	$7,039,010
Accounts Payable, Current	1,860,491				1,317,072				1,860,491	1,317,072		1,860,491
Operating Expense [Member] | NIH & NIAID [Member] | Initial [Member]
Note 13 - Revenue and Concentration of Credit Risk (Details) [Line Items]
Unattained Funds, Contracted Commitment	38,400,000								38,400,000			38,400,000
Other Specified [Member] | NIH & NIAID [Member] | Initial [Member]
Note 13 - Revenue and Concentration of Credit Risk (Details) [Line Items]
Unattained Funds, Contracted Commitment	1,400,000								1,400,000			1,400,000
NIH & NIAID [Member] | Additional [Member]
Note 13 - Revenue and Concentration of Credit Risk (Details) [Line Items]
Unattained Funds, Contracted Commitment	5,400,000								5,400,000			5,400,000	500,000
NIH & NIAID [Member]
Note 13 - Revenue and Concentration of Credit Risk (Details) [Line Items]
Unattained Funds, Contracted Commitment	39,800,000								39,800,000			39,800,000
Revenues									1,797,054	4,421,689	7,032,760	36,800,000
Accounts Receivable, Net, Current	129,019				424,501				129,019	424,501		129,019
Accounts Payable, Current	8,493				27,925				8,493	27,925		8,493
Provision for Other Credit Losses									0
NIH [Member]
Note 13 - Revenue and Concentration of Credit Risk (Details) [Line Items]
Remaining Unattained Funds Contracted Commitment	$3,000,000								$3,000,000			$3,000,000

Note_14_License_Agreement_Deta

Note 14 - License Agreement (Details) (USD $)	1 Months Ended
	Jul. 30, 2011
Up Front License Fee [Member]
Note 14 - License Agreement (Details) [Line Items]
License Costs	$50,000
Total License Fee [Member]
Note 14 - License Agreement (Details) [Line Items]
License Costs	100,000
Annual License Fee [Member]
Note 14 - License Agreement (Details) [Line Items]
License Costs	$75,000

Note_15_Collaboration_Agreemen1

Note 15 - Collaboration Agreements (Details) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Jul. 31, 2013	Dec. 31, 2013	Nov. 30, 2013	Aug. 31, 2013
Note 15 - Collaboration Agreements (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	9,598		9,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$6.60		$6.60
Deferred Credits and Other Liabilities, Noncurrent	$3,066,000		$3,066,000
Notes Payable	19,827,430		7,059,553
Debt Instrument, Increase, Accrued Interest	693,114
Nonsoftware License Arrangement [Member] | Medinet [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Deferred Credits and Other Liabilities, Noncurrent	1,000,000		1,000,000
Below Market Rate Adjustment [Member] | Medinet [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Deferred Credits and Other Liabilities, Noncurrent	3,100,000		2,100,000
Scenario, Plan [Member] | Pharmstandard [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)				499,788
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$5.82
Initial Submission of Application for Regulatory Approval [Member] | Green Cross [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalty Guarantees, Commitments, Amount		500,000
Initial Regulatory Approval [Member] | Green Cross [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalty Guarantees, Commitments, Amount		500,000
Developmental and Regulatory Milestones [Member] | Maximum [Member] | Medinet [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalty Guarantees, Commitments, Amount			9,000,000
Sales Milestones [Member] | Medinet [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalty Guarantees, Commitments, Amount			5,000,000
Sale Option [Member] | Medinet [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalty Guarantees, Commitments, Amount			1,000,000
Maximum [Member] | Pharmstandard [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalties, Percent of Net Sales					20.00%
Maximum [Member] | Green Cross [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalties, Percent of Net Sales		20.00%
Maximum [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalties, Percent of Net Sales	4.00%
Green Cross [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Royalty, Contract Term		15 years
Medinet [Member]
Note 15 - Collaboration Agreements (Details) [Line Items]
Duration After Triggering Event		30 days
Percent of Triggering Events Occured		50.00%
Proceeds from License Fees Received			1,000,000
Proceeds from Notes Payable			9,000,000
Debt Instrument, Face Amount			9,000,000
Debt Instrument, Interest Rate, Stated Percentage			3.00%
Notes Payable	7,600,000		6,900,000
Debt Instrument, Interest Rate, Effective Percentage			8.00%
Debt Instrument, Increase, Accrued Interest	$700,000

Note_16_Facility_Lease_Obligat2

Note 16 - Facility Lease Obligation (Details) (USD $)	1 Months Ended
	Aug. 18, 2014	Dec. 31, 2014
	sqft
Note 16 - Facility Lease Obligation (Details) [Line Items]
Facility Lease Obligation Building Area (in Square Feet)	120,000
Lease Term	10 years
Operating Lease Future Monthly Payments	$46,917
Security Deposit		1,325,000
Lease Agreement, Purchase Option		7,600,000
Lease Agreements [Member]
Note 16 - Facility Lease Obligation (Details) [Line Items]
Investment Building and Building Improvements		3,400,000
Contractual Obligation		$3,400,000

Note_16_Facility_Lease_Obligat3

Note 16 - Facility Lease Obligation (Details) - Future Payments Under The Lease Agreement (USD $)	Dec. 31, 2014
Note 16 - Facility Lease Obligation (Details) - Future Payments Under The Lease Agreement [Line Items]
2015	$394,089
2016	435,359
2017	79,688
Total future minimum lease payments	909,136
Facility Lease [Member]
Note 16 - Facility Lease Obligation (Details) - Future Payments Under The Lease Agreement [Line Items]
2015	375,333
2016	571,445
2017	584,303
2018	597,449
2019	610,892
Thereafter	3,496,201
Total future minimum lease payments	$6,235,623

Note_17_Manufacturing_Research1

Note 17 - Manufacturing Research and Development Obligation (Details) (USD $)	0 Months Ended
	Oct. 29, 2014	Dec. 31, 2014	Oct. 29, 2014
Note 17 - Manufacturing Research and Development Obligation (Details) [Line Items]
		$3,475,552
Invetech Pty Ltd [Member]
Note 17 - Manufacturing Research and Development Obligation (Details) [Line Items]
Deferred Research and Development Manufacturing Service Costs Percentage	30.00%
Maximum Deferred Research and Development Manufacturing Service Costs	5,000,000		5,000,000
Interest Rate on Deferred Research and Development Manufacturing Costs	7.00%		7.00%
Period from Trigger Event for Repayment of Deferred Costs	90 days
Number of Installments for Repayment in One Year	4
Number of Installments for Repayment in Two Years	8
Bonus Payment upon Successful Completion of Clinical Trials Percentage of Payment	10.00%
		3,500,000
Research and Development Obligation Deferred Fees		2,500,000
Research and Development Obligation Estimated Bonus Payment		900,000
Research and Development Obligation Accrued Interest		34,330
Contractual Obligation		$25,000,000

Note_18_Commitments_Details

Note 18 - Commitments (Details) (USD $)	1 Months Ended		12 Months Ended
	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 18 - Commitments (Details) [Line Items]
Operating Leases, Rent Expense, Net			$447,918	$348,191	$361,356
Payments for Fees	$200,000	$200,000
Minimum [Member]
Note 18 - Commitments (Details) [Line Items]
Royalties, Percent of Net Sales			1.00%
Maximum [Member]
Note 18 - Commitments (Details) [Line Items]
Royalties, Percent of Net Sales			4.00%

Note_18_Commitments_Details_Fu

Note 18 - Commitments (Details) - Future Minimum Lease Payaments (USD $)	Dec. 31, 2014
Future Minimum Lease Payaments [Abstract]
2015	$394,089
2016	435,359
2017	79,688
Total minimum lease payments	$909,136

Note_19_Employee_Benefit_Plan_

Note 19 - Employee Benefit Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	25.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$121,399	$101,700	$71,571

Note_20_Net_Loss_Per_Share_Det

Note 20 - Net Loss Per Share (Details) - Basic and Diluted Net Loss Per Share (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 20 - Net Loss Per Share (Details) - Basic and Diluted Net Loss Per Share [Line Items]
Net loss	($16,220,410)	($15,101,017)	($11,983,531)	($10,000,980)	($8,020,922)	($5,672,598)	($5,778,841)	($4,449,202)	($53,305,938)	($23,921,563)	($10,471,330)
Accretion of redeemable convertible preferred stock				-863,226	-477,029	5,325,406	-10,446	-64,940	-863,226	4,772,991	-351,371
Reverse prior accretion on redeemable preferred stock due to reduction in liquidation value of Series A, B, and C										5,657,638
Preferred stock dividend due to exchanges of preferred shares										-14,726,088
Net loss attributable to common stockholders	-16,220,410	-15,101,017	-11,983,531	-10,864,206	-8,497,951	-15,073,280	-5,789,287	-4,514,142	-54,169,164	-33,874,660	-10,822,701
Weighted average common shares outstanding, basic and diluted (in Shares)	19,656,209	19,655,561	19,655,187	10,376,561	234,789	231,084	226,757	226,757	17,367,665	229,865	198,306
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	($0.83)	($0.77)	($0.61)	($1.05)	($36.19)	($65.23)	($25.53)	($19.91)	($3.12)	($147.37)	($54.58)
Convertible Preferred Stock [Member]
Note 20 - Net Loss Per Share (Details) - Basic and Diluted Net Loss Per Share [Line Items]
Accretion of redeemable convertible preferred stock									($863,226)	($884,647)	($351,371)

Note_20_Net_Loss_Per_Share_Det1

Note 20 - Net Loss Per Share (Details) - Antidilutive Securities	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities		6,322,747	2,167,143
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	2,847,097	767,510	366,389
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	82,781	424,961	316,184

Note_21_Selected_Quarterly_Dat2

Note 21 - Selected Quarterly Data (Unaudited) (Details) - Quarterly Data (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Data [Abstract]
Revenue	$303,453	$398,615	$473,163	$798,788	$715,747	$981,247	$1,263,008	$1,461,687	$1,974,019	$4,421,689	$7,039,010
Research and development	13,459,178	12,998,409	10,569,134	8,472,195	7,069,151	5,630,219	6,102,320	5,189,461	45,498,916	23,991,151	17,616,892
General and administrative	2,480,025	2,320,036	1,865,822	1,933,476	1,620,068	1,024,167	939,725	1,078,357	8,599,359	4,662,317	6,135,581
Operating loss	-15,635,750	-14,919,830	-11,961,793	-9,606,883	-7,973,472	-5,673,139	-5,779,037	-4,806,131	-52,124,256	-24,231,779	-16,713,463
Other income (expense), net	-584,660	-181,187	-21,738	-394,097	-47,450	541	196	356,929
Net loss	-16,220,410	-15,101,017	-11,983,531	-10,000,980	-8,020,922	-5,672,598	-5,778,841	-4,449,202	-53,305,938	-23,921,563	-10,471,330
Accretion of redeemable convertible preferred stock				-863,226	-477,029	5,325,406	-10,446	-64,940	-863,226	4,772,991	-351,371
Less: Preferred stock dividend due to exchanges of preferred shares						-14,726,088				-14,726,088
Net loss attributable to common stockholders	($16,220,410)	($15,101,017)	($11,983,531)	($10,864,206)	($8,497,951)	($15,073,280)	($5,789,287)	($4,514,142)	($54,169,164)	($33,874,660)	($10,822,701)
Net loss attributable to common stockholders per share, basic and diluted (in Dollars per share)	($0.83)	($0.77)	($0.61)	($1.05)	($36.19)	($65.23)	($25.53)	($19.91)	($3.12)	($147.37)	($54.58)
Weighted average shares outstanding, basic and diluted (in Shares)	19,656,209	19,655,561	19,655,187	10,376,561	234,789	231,084	226,757	226,757	17,367,665	229,865	198,306

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) - Deferred Tax Asset Valuation Allowance (Valuation Allowance of Deferred Tax Assets [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Valuation Allowance of Deferred Tax Assets [Member]
Valuation Allowance [Line Items]
Balance at beginning of year	$47,945		$39,134		$36,515
Balance at end of year	68,197		47,945		39,134
Charged to expenses	$20,252	[1]	$8,811	[1]	$2,619	[1]
[1]	Impact of providing full valuation allowance against all deferred tax assets since the Company could not assert that it was more likely than not that these deferred tax assets would be realized.